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INTRODUCTION 
Brain metastasis is a condition with high morbidity and mortality. Exact 
incidence of brain metastasis remains unknown. Brain metastasis is the most 
common intracranial tumors in adults. The overall incidence of brain metastasis 
has drastically increased due to improved detection and treatment(1). MRI and 
other imaging modalities have improved the detection and exact localization of 
these masses. The studies say that 9 to 11 percent of cancers develop cerebral 
metastasis(2). In the past the median survival for the patients with brain 
metastasis on steroids and supportive care was only 2 months.(3) So the 
treatment of brain metastasis in favorable patient mainly concentrated on 
maintaining quality of life (QoL) and neurocognitive function.  
WBRT is a standard treatment for patients with late stage metastatic 
brain tumors. (4)Until today there are no randomized control trials to prove the 
benefit of any intensified treatment beyond WBRT(5). WBRT is a palliative 
process for patients with brain metastasis that reduce symptoms and improve 
quality of life. In brain metastasis median survival is considered to be low and 
estimated to be around 7 months.(6)  In contrast a small group of cases with 
brain metastasis survive beyond 5 years.(7)so the survival of the patients is 
unpredictable and various palliative measures are absolutely necessary to 
reduce the suffering. WBRT has the significant capacity to reduce tumor mass. 
But this treatment is not without side effects. The greatest fear with the 
application of WBRT is the fear of neurocognitive decline and in rare cases of 
dementia. Many experiments conducted on animal models have proved that the 
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micro vascular damage and cell death due to radiation exposure were the main 
reason for cognitive deficit. The decline in cognition in cancer patients may be 
due to several factors ranging from primary mass effect, radiation, surgery, 
secondary depression, anxiety, sleep disturbance, chemotherapy, 
immunological and hormonal reasons. So defining the exact cause of cognitive 
decline is impossible. But in terms of temporal correlation cognitive decline is 
definitely seen with WBRT. 
The patients with secondaries to the brain are often debilitated and 
hence measurement of the cognitive decline in this group of patients is a 
challenge. The main component of this WBRT related cognitive decline is the 
immediate and delayed verbal memory(8). But the decline in performance is 
seen in various other neurocognitive and executive functions(9). Multiple 
studies are done in this area but none could specifically confirm the change 
happening with WBRT exposure. In terms of the duration and pattern of 
change specific studies are still not available. Studies say that early cognitive 
decline is seen in 1 to 4 months of exposure to WBRT(10). The effects seen in 
due course are late cognitive effects. Several studies have been done in this 
subject but have given unequivocal results.  
Cognitive decline is said to be the main reason for poor quality of life in 
majority of cancer patients. But general cognitive function and quality of life 
was only partially affected by it. Since the neurocognitive decline and poor 
quality of life occur in a sequence, the present treatment modalities mainly 
concentrate on delaying the decline in neurocognitive function(11). 
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The studies in this area are very few and mainly done in retrospective 
way. But none of the studies could definitely provide the proof of association 
between WBRT and Neurocognition. The reason is that many patients in 
addition went on to have a surgery and chemotherapy which may have had an 
effect on cognition. With the developments in radiation technology like 
stereotactic radiotherapy the precision of delivery of radiation has 
improved(12). But in many centers WBRT is still used for its benefits and 
efficacy.  
With the developments in diagnostics, imaging and radiation 
technology, treatment of metastases has become a therapeutic challenge.  
So we performed a prospective study on patients who were on WBRT 
and made an attempt to assess the correlation of WBRT on Neurocognition. 
We also compared their quality of life and indirectly assessed their quality of 
living. 
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REVIEW OF LITERATURE 
Whole brain radiotherapy 
Metastasis may spread from any region of the body to brain. The 
primaries are usually found in lungs, breasts and gastrointestinal region. The 
studies found that 30% to 40% of all the cancers metastasize to the brain. Until 
1950s there was no specific therapy that could target these inoperable 
metastatic tumors. The advent of radiotherapy marked the first step in treating 
and palliating these tumor afflicted people. The benefit of WBRT was proved 
beyond doubt by 1970s and later proved to be the gold standard in treating 
brain metastases. It was the work of Chao et al that paved the way in 
establishing the effect of radiation.(13) He claimed that 63% of the effects of 
tumor can be reduced with radiation exposure and went on to tell that there 
were patients who were radio resistant. 
Whole brain radiotherapy (WBRT) is a mainstay of treatment and 
palliation in patients with brain metastases. It consists of administering 
therapeutic doses of radiation to the tumor sites in calculated fractions. WBRT 
is administered to a wide variety of conditions ranging from primary brain 
tumors, secondary metastasis; prophylactic cranial irradiation etc. The 
secondaries with multiple masses often prevent surgical intervention and then 
the only intervention of choice would be WBRT or chemotherapy. The unique 
feature of WBRT is that the treatment does not depend on histological type of 
mass, as it works even on the masses that are said to be radio resistant. Thus by 
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destroying histologically varied tumor masses WBRT may be considered gold 
standard in treating brain metastasis. 
WBRT works on 4 main principles(14) 
• Repair – WBRT given is lesser calculated doses will give required 
duration for normal cells to repair  
• Reoxygenation- hypoxic areas in tumor mass are radio resistant, but 
lower doses of radiation permit required amount of circulation. 
• Redistribution- tumor cells in S phase are resistant to radiation, so 
enough time must be given between each radiation cycle to permit the 
differentiation of cells. 
• Repopulation- tumor cells on irradiation grow too quickly, hence 
excess time between radiation cycles will allow tumor cells to 
repopulate. 
Role of WBRT, in the treatment of brain metastasis.   
Multiple studies have shown that 64% to 83 % of the patients gain 
improvement with WBRT. The studies say that survival benefit of 6 to 8 
months is obtained with WBRT. Usually the radiotherapy is administered as 
30Gy in 10 fractions over 2 weeks. Many alternative dose regimens have been 
established, but the risk benefit response [tumor mass clearance Vs side effect] 
was found to be best with the above regimen for brain metastasis. Regarding 
cognitive outcome in alternative regimens, not many studies have been done 
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but with higher doses of radiation the physical complications have found to be 
seen beyond doubt. So with respect to alternative regimen multiple prospective 
studies are needed to find the exact outcomes in terms of risk and benefit in the 
outcome. The median survival obtained with patients treated with WBRT was 
found to be 4.9months.(15) 
Radiation toxicity(10) 
Early side effects 
The toxic side effects that are seen in first few days to weeks of 
treatment of radiotherapy are called early side effects. It consists of headache, 
alopecia, nausea, and vomiting and reduced appetite. These are often self 
limited and subside on their own or with minimal intervention. Another 
common early side effect is cerebral edema which is often generously treated 
with corticosteroids. Encephalopathy, herniation and death are very rarely seen 
early side effects. 
Early to delayed side effects 
This includes anorexia, vomiting, headache, fatigue, memory decline 
and focal neurological deficits. Rarely in pediatric population is a condition 
called somnolence syndrome seen with above symptoms and irritability. Even 
the early to delayed side effects are often self limited. 
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Late side effects 
The side effects occurring after 90 days of administering the radiation 
therapy are late side effects. According to Radiation Therapy Oncology Group 
[RTOG] late side effects have poor outcome and are not self limiting. So 
generally these late side effects with preserved cognition determine the quality 
of life of the patient. Meta analysis done by Tallet et al with 7 studies was 
useful in showing that there was a cognitive decline of 31% to57% in 3 
months(16). Same study also predicted a decline in cognition from 48% to 89% 
in 1 year.  The cognitive decline caused by the growth of tumor mass is 
significantly higher than the neurocognitive decline due to WBRT. Hence it is 
used as a successful treatment modality for terminal stage cancers and multiple 
metastases. 
Leukoencephalopathy is another serious side effect(10). It presents as 
dysarthria, ataxia, neurocognitive dysfunction, seizures and lethargy. 
Periventricular white matter changes and ventricular enlargement on CT and 
MRI scans help in diagnosis and management. 
Radiation necrosis is the most serious side effect seen very rarely. It 
presents with necrosis of blood vessels and endothelium. This extensive 
vascular necrosis can lead to serious neurological deficit or death. 
A study by Kondziolka et al(17) studied the patients perspective 
regarding complications after WBRT. He reported that 88% have hair loss, 
short-term memory (72%), long-term memory (33%), concentration (61%), and 
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depression (54%). He also showed in his study that 63% of the patients on 
WBRT thought that they had side effects from taking the therapy. 
Stereotactic radio surgery is emerging as a new development in treating 
cranial metastasis. It helps to deliver strong doses of radiation to metastatic foci 
in the brain avoiding undesirable exposure to normal tissue. But many experts 
in the field strongly believe that STEREOTACTIC RADIOSURGERY will 
often fail to irradiate micro metastasis in other areas of brain. Current imaging 
techniques are still not advanced in identifying the micro metastasis in the 
brain. Thus WBRT helps in irradiating the tumor tissue and destroying even the 
micro metastases and so helps in killing all the tumor cells in brain.  
 
Figure 1, Factors effecting Neurocognition in cancer patients 
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Neurocognition in WBRT 
Cancer treatment associated cognitive decline is a serious matter of 
concern. The major manifestation of WBRT is the development of 
neurocognitive impairment. The time duration for WBRT induced cognitive 
decline is found to vary among various studies.(18) The impairment ranges 
from inattention, impaired short and long term memory, poor reasoning and in 
the end frank dementia. Even with the development of several newer advances 
like Stereotactic radio surgery; WBRT still continues to be widely used due to 
the total survival benefit obtained out of it.  
Vascular hypothesis of radiation induced brain injury(19) 
Radiation has profound effect on the neurons and surrounding 
vasculature(20). Vascular theory mainly argues that radiation exposure causes 
damage to the endothelial cells and suppresses its proliferations. Thus it breaks 
down blood brain barrier and leads to inflammatory damage to the interstitium. 
Several studies in this regard have shown the development of vessel wall 
thickening, vessel dilation, and endothelial cell nuclear enlargement in cells 
exposed to radiation(20). Studies by Warrington et al have shown that in rats, 
the radiation therapy causes exposure of the interstitium and capillary 
rarefaction. Inflammatory cytokines, TNF alpha, IL-12, IL 18 are mainly 
involved in the damage of the tissues. Due to the above reasons the blood brain 
barrier gets breached causing the exposure of matrix metalloproteinase – 2 and 
metalloproteinase – 2 tissue inhibitor(21). Radiation also causes degradation of 
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collagen type IV, which is an extracellular matrix component of the blood 
vessel basement membrane, and report changes in the mRNA and protein 
expression of VEGF, Ang-1, Tie-2, and Ang-2.(22) The earliest known damage 
is seen at 10 weeks post radiation. There is profound micro vascular deficit, 
metabolic disturbance, immune response and neuronal hypoxia which is 
together said to be responsible for cognitive decline occurring after 
WBRT.(20).  
Next culprit is hippocampal neurogenesis. Neurocognitive impairment 
occurs due to problem in hippocampal neurogenesis.(23). Radiation-induced 
cognitive impairment occurs in up to 90% of adult brain tumor patients who 
survive >6 months after whole brain radiotherapy(24). 
Dentate gyri, CA 3, CA 1 are the predominant areas of hippocampal 
neurogenesis. Radiation induced damage of these areas are associated with 
poor regeneration of neurons and hence said to be the cause for cognitive 
decline.  
Majority of the studies mainly concentrate on the hippocampal injury for 
cognitive decline.(24) Other possible causes include: 
• NMDA receptor alterations. 
• Disrupted arc expression in hippocampal neurons 
• Genetic factors 
• Neuronal inflammation/ oxidative stress. 
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Neurocognitive tests show varied results based on the domain measured in 
different population. 
 Cellular and molecular pathway of neurocognitive decline(25) 
Molecular mechanism for radiation induced cognitive decline is ill-
defined. In the past it was considered that radiation induced DNA damage was 
the cause of neuronal cell death. There was also the endothelial cell death and 
glial cell loss which was indirectly considered to cause cognitive decline. The 
latest research with the use of fMRI scans has given a different picture. The 
present hypothesis is that cognitive decline is a manifestation of complex 
interaction between various neuronal cells. Astrocytes, microglia, neurons and 
oligodendrocytes interact in a complex way with, endothelial cells to produce 
dynamic changes. 
Parenchymal hypothesis of brain injury(19) 
Oligodendrocyte 
This theory was basically focused on the oligodendrocyte which is 
involved in the formation of myelin sheath. Oligodendrocyte type-2 astrocyte 
(O-2A) progenitor cell is the cell that is necessary for the formation of 
oligodendrocytes(26). These progenitor cells lose their reproductive capacity 
on exposure to whole brain radiation therapy in the rats. The above hypothesis 
states  that radiation induced loss of O-2A progenitor cells causes failure to 
replace oligodendrocytes which ultimately results in demyelination and white 
matter necrosis. After whole brain irradiation there was a decrease in number 
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of oligodendrocytes in 24 hrs after irradiation but there was no change in the 
number of myelinated axons, myelin sheath thickness, and the cross-sectional 
area of myelinated axons in cognitively impaired rats after 12 months of whole 
brain irradiation dose of 40 Gy delivered twice a week for 4 weeks to middle-
aged rats(27). Thus the above theory is still unclear in explaining all the 
questions regarding cognitive deficits on radiation exposure. 
Astrocytes 
Astrocytes constitute more than 50% of the glial cell population. They 
are involved in modulation of synaptic transmission and secrete important 
neurotrophic factors such as ﬁbroblast growth factor to promote neurogenesis. 
They also protect neurons and protect endothelial cells. They form a 
component of blood brain barrier and secrete many pro inflammatory 
cytokines.(28) In case of injury these astrocytes undergo hypertrophic changes 
and secrete pro-inﬂammatory mediators such as cyclooxygenase (Cox)-2 and 
the intercellular adhesion molecule (ICAM)-1. During inflammation there is 
increased expression of glial ﬁbrillary acidic protein (29)and breach in blood 
brain barrier. The resulting gliosis causing radiation induced edema is said to 
be the likely cause of brain injury due to irradiation. 
Microglia 
Microglia constitutes the cells involved in phagocytosis. They maintain 
homeostasis by secretion of neurotrophic factors.(30) Irradiation of these cells 
results in rounding of cells, retraction of cell processes, formation of 
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chemokines and reactive oxygen species. Rat models have shown increase in 
number of activated microglia around hippocampus with increased pro 
inflammatory markers after radiation exposure.(31) Anti inflammatory drugs 
like indomethacin and ramipril reduce activated microglia in the hippocampus 
and perirhinal cortex(21). Thus in rodents they are shown to prevent radiation-
induced cognitive impairment. 
Neurons 
Historically neurons were considered to be radio resistant. But the newer 
studies have shown that radiation causes changes in hippocampal neurons, in 
synaptic connectivity and gene expression. Irradiating the rat brain causes. 
(i) Neuronal receptor expression of the immediate-early gene activity-
regulated cytoskeleton-associated protein (Arc)(32) 
(ii) N methyl-D-aspartic acid (NMDA) receptor subunits 
(iii) Glutaminergic transmission 
(iv)  Hippocampal long-term potentiation(33) 
All the above changes are considered to be important for normal 
cognitive functioning. Thus, a dynamic interaction of all the radiation induced 
changes in all the cells types is said to be the reason behind the neurocognitive 
change occurring after radiation exposure. 
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Analysis on glial clonogens in rat models 
Experiment on rat with fractional whole brain irradiation resulted in 
reduced endothelial cells, vascular length and density. Two months later the 
tissue hypoxia and capillary rarefaction increased in hippocampal areas. When 
fetal neural stem cells were given IV to these rats the cognition in these rats 
improved. After each 5Gy fraction of whole brain radiotherapy the IV neural 
stem cells were supplemented and cognition was maintained with no alteration 
in vascular length or density. 
Oligodendrocyte type-2 astrocyte (O-2A) progenitor cell is said to be the 
primary cell death occurring in WBRT. The radiation induced death of these 
cells results in demyelination and white matter necrosis. This is considered to 
be a possible cause of cognitive decline. But the above change is only 
considered to be transient. 
Radiation exposure in rodents causes following changes(25) 
• Hippocampal long term potentiation 
• Neuronal receptor expression of the immediate-early gene activity-
regulated cytoskeleton-associated protein (Arc) ,  
• N-methyl-D-aspartic acid (NMDA) receptor subunits, 
• Glutaminergic transmission 
Wu et al(34) showed that radiation exposure to rat brains resulted in 
reduced tyrosine phosphorylation, reduced exposure of NMDA receptors and in 
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contrast increased expression of GABA receptors. NMDA (N-methyl D-
aspartate) and AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid) receptors are responsible for excitatory signaling in hippocampus. 
Whereas, the GABA (gamma-amino butyric acid) receptors are responsible for 
inhibitory neurotransmission. Thus above receptors and the neurotransmitters  
play unique role in managing neural plasticity and in turn are vital for normal 
Neurocognition. 
Radiation leads to acute changes in tyrosine phosphorylation in various 
research models. It is found that trafficking of neurotransmitter receptors to and 
fro from the cell surface is dependent on tyrosine phosphorylation. Thus, 
tyrosine phosphorylation-dependent trafficking of excitatory NMDARs to the 
synapse plays a role in LTP. 
1)  Radiation Alters NMDA receptor phosphorylation thus changes 
NMDA and GABA A receptor Localization. 
2)  Radiation Alters NMDA and GABA responses and thus acutely 
Inhibits Long term potentiation. 
These changes caused alteration in synaptic responses and reduction of 
long term potentiation which in turn resulted in reduced cognition. 
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Neuro inflammatory model 
Pathophysiology of neuro inflammation(25) 
• Elevated inflammatory cytokines post radiation up to 6 months 
• Increased activation of microglia 
• CCR2 receptor hyper activation in sub granular zone 
• Persistent astroglial and microglial activation. 
 
Figure 2, Pathophysiology of cognitive impairment in patients on WBRT. 
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Neural circuits 
Hippocampal formation (dentate gyrus and cornu ammonis) are 
considered vital for memory formation. It is involved in learning, 
consolidation, retrieval of information, and construction of new memories. 
Hippocampal injury results in, the impairment of declarative memory  which is 
the conscious recollection of facts and events(35). But emerging research is of 
the opinion that entire limbic circuit is important for normal cognitive function. 
Limbic structures are 2 arch like circuits that are surrounded by ventricles. The 
inner arch consists of amygdala, hippocampus [cornu ammonis and dentate 
gyrus], fornix, and mamillary bodies. The outer arch consists of 
parahippocampal gyrus, cingulum, cingulate gyrus, induseum griseum, and 
paraterminal gyrus. The inner and outer arches are separated by the 
hippocampal sulcus and corpus callosum.(36) 
This circuit is critical to a number of brain functions: integration and 
consolidation of new memories, emotional responses and behavior, special 
orientation, autonomic responses to external stimuli, and ﬁne motor 
coordination (among others).(36) The two structures closely associated with the 
hippocampus include the amygdaloid complex and parahippocampal gyrus.(36) 
The parahippocampal gyrus is critical to memory encoding and retrieval of 
memories, and its ventral-most portion, called the entorhinal cortex, is the 
important source of aﬀerent signals to the hippocampus. The amygdaloid 
complex, or amygdala, is involved in memory modulation (required for long-
term memory consolidation and the association of memory with emotional and 
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physiological states) and emotional learning (fear reactions, imprinting, 
breeding behaviors, etc.).(36) The three structures— the hippocampal 
formation, parahippocampal gyrus, and amygdaloid complex—form a 
functional unit within the medial temporal lobe and is responsible for true 
memory consolidation and learning(36). 
The cingulate gyrus is involved in attention, concentration and regulated 
autonomic response to emotional stimuli. The cingulum is a white matter tract 
adjacent to the cingulate gyrus which connects the parahippocampal gyrus to 
cingulate gyrus and prefrontal area. Fornix and mamillary bodies are other 
structures closely associated with limbic system. In this way the limbic system 
forms vital circuit in connecting hypothalamus, thalamus, prefrontal, 
orbitofrontal cortices, and nucleus accumbens. The function of the circuit as a 
whole is to process memory, support learning (cognitive, emotional, and 
autonomic), regulate emotional states, and assist in spatial orientation. Since 
the above circuit is involved in so many vital cognitive functions, the radiation 
exposure to it manifests as late toxicity. 
Thus from the above studies we can know the possible reason behind the 
cognitive decline due to whole brain radiotherapy. 
Studies on Neurocogniton of patients on WBRT 
MMSE was used for the analysis of the cognitive change in WBRT(9). 
In a large scale study done by Sun et al the MMSE assessment showed 36 % of 
the population having impaired scores in MMSE after 3 months of whole brain 
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radiotherapy. The study by Aoyama et al showed that 5% patients with 
impaired MMSE at 2months which reduced to 14% and 28 % at 3 and 6 
months respectively. This study basically used subjects with MMSE score >27 
for the analysis. The results showed that up to 40 % of the patients had decline 
in MMSE by 12 to 18 months. Thus these studies showed the importance of 
MMSE as an important tool in assessment of WBRT patients. Another study 
done by Corn et al with 92 subjects showed that exposure of 37.5 
Gy/15fractions/19 days led to drop in MMSE scores in 23% by 2 months and in 
up to 40% by 18 months. But the largest study(37) by Regine et al with 182 
subjects using 30 Gy/10 fractions/12 days. The above showed 46 % having 
decline in MMSE scores in just 3 months. 
Murray et al(38) published a study by comparing  the MMSE of patients 
on WBRT with 2 different regimens. He enrolled 445 patients into this phase 3 
trial to compare 54 Gy {1.6 Gy b.i.d} against 30Gy in 10 fraction using 
MMSE. Study went on from 1991 to 1995 with various assessments. MMSE 
scores among the participants ranged from 11 to 30. He also considered that 
MMSE < 23 might have possible dementia which was in fact seen in 16 % of 
cases before the treatment.(38) The median survival in this study was 4.2 [S.D 
3.7-5] months at 95 % C.I. 63 patients died before MMSE was reviewed. So 
MMSE was reviewed only for patients who had long term survival. This study 
concluded that MMSE is a good scale to assess neurocognitive decline in 
WBRT patients. It also stated that 30Gy in 10 fraction prevented MMSE scores 
of patients with long term survival to drop less than 23. The poor prognostic 
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factors were males, old age, low MMSE and early drop in MMSE below 23. 
Thus most of the above studies were significant in showing the importance of 
MMSE in assessment of cognitive decline in WBRT patients. 
Hopkins verbal learning test was used to assess the verbal learning skill 
in subjects in several studies. This scale assesses the verbal learning ability of 
the patients. Several studies were done in this area giving significant results. 
Tanaka et al(39) in 2014 used HVLT on patients undergoing WBRT with 
different fraction and showed significant results. In this study using Japanese 
version of HVLT, 40% of the study population showed significant decline in 
total recall scores with 35Gy fraction at 4 months. The decline with 30 Gy, 25 
Gy were 7% and 0% respectively from the baseline. But the delayed 
recognition scores in 4 months declined by 2 points in 47% and 13% with 35 
Gy and 30 Gy respectively.  
A significant study with respect to HVLT was by Vinai godi et al (86) 
which showed the changes in verbal memory. This study compares the HVLT 
scores with total hippocampal sparing WBRT against the controls drawn. This 
study shows the decline that happens in Neurocognition when hippocampus is 
exposed to radiation. Here the controls that were exposed to radiation showed 
up to 30% drop in Neurocognition specifically in HVLT scores. Even among 
the 113 cases taken for the study 46 cases had died by 6 months. On analyzing 
the HTLV scores of the patients who died within 6 months there was a 
statistically significant drop in HVLT scores. Among the rest of the patients 
who were exposed to HA WBRT there was 7 % decline in Neurocognition 
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which was not found to be statistically significant. Thus above study could 
conclude that neurocognitive decline occurs due to radiation and is indirectly a 
factor of age as it determines stem cell population in the dentate gyrus of 
hippocampus.   
A study done to correlate hippocampal dosimetry on cognitive outcome 
was done on    24 patients(40).  It showed that when hippocampus is totally 
excluded from the radiation field with hippocampal sparing radiotherapy 
neurocognition can be partially preserved. 
Another study was done by Sun et al(41) which significantly depicted 
the memory decline with exposure to WBRT. Total of 356 patients were 
recruited for the study. Patients were the ones who were suffering from 
advanced Non small cell lung carcinoma. All the set of baseline neurocognitive 
assessment was done on the patient with quality of life evaluation. MMSE was 
the scale which was used to evaluate the patients for cognitive impairment. 
MMSE was used on the patients at 3, 6 and 12 months.  
An interesting finding is that there was statistically significant difference 
in MMSE scores between WBRT and controls at 3 months [p= 0.04]. But there 
was no statistically significant drop in MMSE scores over 12 months [p=0.60]. 
HVLT was also used on the subjects in this study which gave valuable results. 
HVLT immediate recall showed most significant result at 3 months with 
p=0.001. The result also remained significant at 6 months [to a lesser extent 
with, p=0.045] and at 12 months [p=0.03]. HVLT Delayed Recall also had the 
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most signiﬁcant change at 3 months (P =0 .001). But the scores showed no 
significant difference at 6 months [p=0.81] and later again showed significant 
difference at 12 months [p=0.008]. This clear difference showed that MMSE 
was less sensitive than HVLT in measuring the cognitive decline occurring due 
to radiation exposure. This study further analyzed the quality of life of patients 
on WBRT.  They used the European Organization for Research and Treatment 
of Cancer (EORTC), Quality of Life QLQ-C30 Questionnaire (QLQ-C30) and 
BN20 for assessing the quality of life.  
The study showed that there was no significant difference in Quality of 
life scores at 1 year after exposure to whole brain radiotherapy. They also 
mentioned the loss of follow up as one of the major limitations while arriving 
at above scores. The compliance rate fell to 34% for neurocognitive function 
and 37% for the quality of life scores after 12 months of follow up. The decline 
in neurocognitive function here is similar to a study by Wolfson et al(42) which 
found a signiﬁcant increase at 1year of  Neurocognitive function decline in the 
higher-dose cranial irradiation arms (36 Gy) compared to the standard-dose 
arm (25 Gy; P = 0.02). 
A study on cognition by Welzel et al (43) was done on 44 participants. 
He clearly showed that a Neurocognition decline occurs following WBRT. But 
the unique feature is that memory decline is specifically seen immediately in 
patients with brain metastasis and not in patients without metastasis. But after 6 
to 8 weeks decline is seen in patients with and without metastasis. The deficit is 
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significantly associated with verbal memory but is not to be taken as a reason 
for quitting WBRT. 
Another study by Roger el al(44) was done on children receiving 
radiotherapy and chemotherapy. It showed that the children receiving RT 
showed significant reduction in their IQ scores. Overall study follow up of 2 
years there was a drop in verbal and performance IQ scores by 14 points (105 
to 91). The younger the age of child the severe was the decline in IQ. Children 
with age lesser than 7 years, had 25 point drop in IQ scores over 2 years. The 
drop in IQ was seen mainly in visual-motor; fine motor, visual-spatial skills 
and memory function. Authors were seriously concerned with the cognitive 
decline happening in the children as the life span of the children increased. 
Brain atrophy is another manifestation of whole brain RT which was 
shown by Yuta shibamoto et al.(45). They studied on 101 subjects with median 
age of 62 years. Patients with minimum MMSE of 21 and above with no prior 
brain surgery were only selected for this study.  Radiation of 40Gy as 2 Gy/ 
day was administered over4 weeks. Cerebrospinal fluid-cranial ratio [CCR] 
was used to measure the brain atrophy. Neurocognitive assessment was done 
with MMSE scores. Difference in brain atrophy and MMSE scores were 
compared with Fishers exact test. They clearly showed mean atrophy index of 
1.24 ± 0.39 (SD) at 6 months and 1.32 ± 0.40 at 12 months, and among 
them18% and 28% had increase in score by 30% or greater respectively. The 
mean MMSE scores almost remained constant according to this study. The 
scores dropped by 4 or more points in 11% at 6 months and 12% at 12 months. 
 24 
Since MMSE is less sensitive and covers few domains they recommend group 
of neuropsychological tests to find these subtle changes. So this study showed 
that brain atrophy may or may not be associated with change in MMSE 
scores.(46) 
The study by Aoyama et al was very significant in showing the effect of 
WBRT on STEREOTACTIC RADIOSURGERY patients. The study says that 
STEREOTACTIC RADIOSURGERY alone is better than WBRT in 
preventing Leucoencephalopathy, cognitive decline and other side effects.(47) 
In contrast avoiding WBRT is associated with significant chance of tumor 
recurrence and death among the patients with brain metastasis. This tumor 
recurrence in turn causes functional deterioration and poor quality of life.(37) 
This study enrolled 132 patients and went on for 3 years. Patients were 
randomized to two groups and one group was treated with STEREOTACTIC 
RADIOSURGERY alone and other group was given STEREOTACTIC 
RADIOSURGERY+ WBRT. WBRT was given as 30Gy in 10 fractions in 2.5 
week but was adjusted based on the STEREOTACTIC RADIOSURGERY 
dosage. STEREOTACTIC RADIOSURGERY dosage was reduced by 30% 
when combined with WBRT. Only 92 patients were available for follow up 
review with MMSE scores.  After the exposure of the patients for radiation 
MMSE scores were recorded and analysis done. Among the patients exposed to 
STEREOTACTIC RADIOSURGERY+ WBRT, 14 out of 36 cases had 
significant decline in MMSE scores. In contrast among patients with 
STEREOTACTIC RADIOSURGERY alone only 12 out of 46 patients had 
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drop in MMSE scores. This study showed that when WBRT is combined with 
STEREOTACTIC RADIOSURGERY gave poor outcome in terms of 
Neurocognition as measured by MMSE. 
A study by Silber et al(48) researched on a group of children suffering 
from acute lymphoblastic leukemia and medulloblastoma or posterior fossa 
tumor. Using multiple linear regression model they demonstrated that higher 
the age lesser is the decline in IQ scores with radiation exposure. With the 
exposure of 36Gy the child scored 8.2 points lesser scores in IQ assessment 
than 24 Gy and 12.3 points lesser than in those who were exposed to 18 Gy. 
  Gregor et al(49) performed the evaluation of neuro psychometrics of 
long term tumor survivors under remission. 30 patients who were long term 
survivors following irradiation were recalled for study. Patients who were 
treated initially before 1987 were given WBRT [n = 16] and later patients were 
treated with focused irradiation [n= 14].The test basically concentrated on 
visuospatial organization, visual memory, and complex information processing.  
By analyzing the 16 patients who were on whole brain irradiation he found that 
WBRT caused significant decline is cognition compared to focused irradiation. 
But the IQ was comparable to pre morbid levels in both groups .(49)The 
univariate analysis in this study proved that radiation volume and time from 
treatment made the difference and caused the cognitive decline. Multivariate 
analysis by logistic regression on the samples proved that the reason for 
neurocognitive decline is WBRT exposure. 
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An article by Stephen lutz(50) appeared in cancer which described the 
radiation induced damage to the cortex. The author describes that palliative 
care in a highly debilitated group of patients should be done with minimum 
number of appointments at hospital. So shorter treatment courses to reduce the 
burden of side effects is more beneficial for the palliative patients. He further 
explains that radiotherapy causes serious damage to neural cells resulting in 
apoptosis and vasculopathy. This he tells is the reason for the cognitive decline. 
Author is also of the opinion that mild cognitive decline at times starts to arise 
even before the cranial radiotherapy. In case of combined therapy decline in 
Neurocognition is seen in verbal memory, frontal lobe dysfunction, and motor 
incoordination. He criticizes that present palliative care oncologists are 
reluctant to treat with short course WBRT for patients’ in spite of knowing the 
physical and neurocognitive side effects. (51)He went on to tell that there are 
several experiments on rats which demonstrated radiation induced damage 
resulting in cognitive impairment. 
Wolfson et al(52) performed a study on 264 Small cell lung carcinoma 
cases [131 in Arm 1, 67 in Arm 2, and 66 in Arm 3]. The study was done to 
measure the incidence of chronic neurotoxicity among patients exposed to 
cranial irradiation. The participants in this study had actually achieved 
remission with chemotherapy.  He randomized the participants into 3 groups 
i.e. Arm 1 – total 25 Gy in 10 fraction,  Arm 2- total 36 Gy [2 Gy per day over 
18 days], Arm 3 total 36 Gy [24 twice daily fractions with each session having 
1.5 Gy]. They applied multiple neuropsychological batteries on the patients. 
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After the analysis they showed the cognitive decline was more significant in 
the higher radiation exposure [i.e. in arm 2 and 3] compared to lower radiation 
[arm 1] with p = 0.02.  
The study showed that neurocognitive decline was significantly seen in 
36 Gy group which was seen clearly in at least one definite cognitive function 
Neurocognitive decline was seen in upto 96% of patients of 36Gy group while 
it was seen in 60% of 25 Gy group. Assessments showed abnormalities in 
language, visual and spatial scanning, attention, sequencing, and speed among 
all three arms. The neurocognitive impairment was attributed to the effects of 
chemotherapy on the brain, a paraneoplastic syndrome, aging, an immunologic 
dysfunction, or even microscopic cranial metastases at diagnosis resulting in 
frontal or sub cortical cognitive defects. In contrast the study showed that there 
was no significant difference in terms of survival (50% of both the group were 
alive at 1 year). 
A study in the journal Neurology by Deangelis(53) dealt with rare 
neurocognitive manifestations of radiation exposure. He reported that 12 
patients exposed to WBRT went on to develop frank dementia with ataxia in 
median duration of 14 months. He also observed that severe disabilities lead to 
death in 7 patients. The earliest case he reported was a severe neurocognitive 
decline with dementia in 5 months. He showed the incidence of dementia 1.9% 
and 5.1% patients in 2 different populations which should be confirmed with 
further studies. 
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  The degree of neurocognitive outcome is worrisome according to most 
of the studies done above but it was mostly shown without categorizing the age 
group of the patient’s (54).Benjamin Corn and associates in their study 
published in 2007 made the necessary adjustments for age and education. In 
this study they compared the effect of radiation on patients due to WBRT alone 
against WBRT with thalidomide. This multicentre study used 157 patients in 
each arm applied total of 37.5 Gy as 2.5Gy per fraction. MMSE and SQLI 
(Spitzer quality of life) scales were used for this study. After the study they 
concluded that neurocognitive decline was definitely seen after WBRT. As 
they considered MMSE as non specific tool for assessment of Neurocognition, 
they compared the patient’s age and education to MMSE scores and made 
necessary corrections to arrive at more specific scores. In later analysis they 
concluded that thalidomide doesn’t play a special role in improving 
Neurocognition during WBRT. 
Pospisil et al (55)performed an advanced research using N Acetyl 
aspartate as a marker in post WBRT. Using multi voxel MR spectroscopy they 
tried to measure the (ht-NAA) N-acetyl aspartate concentration in the 
hippocampus of patients who underwent WBRT. They studied 35 patients with 
brain metastasis with multiple verbal and memory scales. Follow evaluation 
was done on 18 patients at 4 months post WBRT. The concentration of ht-NAA 
dropped significantly after radiotherapy on both left (8.64–7.60 mM; −12%, 
95%CI: −7.9 to −16.2%) and right (8.52 –7.42 mM; −12.9%, 95%CI: −7.6 to 
−16.4%) hippocampus. But the reduction in quality of life was not related to 
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the change in concentration of metabolite. Thus the study was helpful in giving 
some practical insight into the neurocognitive decline with WBRT. It also 
showed that hippocampal ht-NAA levels may be useful as a biomarker for cell 
death in WBRT patients. 
When brain metastasis cannot be resected surgically then radiotherapy is 
the treatment of choice.(56) But all tissues are not amenable to radiotherapy. In 
this condition we use certain tumor selective chemicals that increase the effect 
of radiation on the tumor mass. Motexafin gadolinium (MGd) is a new drug 
used with WBRT. Motexaﬁn gadolinium (MGd) targets tumors sele ctively and 
generates reactive oxygen species intracellularly, lowering the apoptotic 
threshold to radiation and chemotherapy. It increases tumor radiation response 
in vivo in preclinical models. MGd is paramagnetic, and previous clinical 
studies have demonstrated tumor localization using MRI.  
Meyers et al(56) performed this study by recruiting 401 patients. They 
tried to find the neurocognitive benefits of using MGd with WBRT. 401 
patients were randomized in WBRT + MGd [5 mg/ kg/day] or WBRT alone. 
Later the randomly divided patients were exposed to 30Gy of WBRT. Among 
the participants 50.8% of patients had metastasis only to brain and 80.1% had 
multiple metastases. Majority of the patients completed neurocognitive 
assessment but, 363 (90.5%) patients had impairment of one or more 
neurocognitive tests at baseline. Univariate and stepwise logistic regression 
analyses of global neurocognitive impairment was done to get the result. The 
results showed that in contrast to WBRT alone, patients on WBRT with MGd 
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had prolonged time-to-neurocognitive progression for memory and executive 
function. Hazard ratio was found which favored the use of Motexafin 
gadolinium with WBRT.  
The overall neurocognitive scores deteriorated over time. The study 
compared neurocognitive function against survival of the patients.  They found 
that impairment in memory (HVLT recognition, recall, and delayed recall), 
motor speed and dexterity (peg board test for dominant and non dominant 
hands), executive function (Trail making Test B), and global neurocognitive 
impairment (> three tests impaired) determined poor survival. A multivariate 
Cox proportional hazards analysis of survival with all eight neurocognitive 
tests included in the model showed that HVLT recognition and recall served as 
independent predictors of survival (P = 0.0323 and P = 0.0342,respectively). In 
this study neurocognitive assessment was also used as an objective measure for 
comparing tumor growth, number and survival. Neurocognitive scores where 
highly correlated with tumor size at baseline and not statistically correlated 
with number of brain metastasis. Thus study suggested that cognition is mainly 
affected by tumor burden and not by number of tumor masses. The study 
showed that the neurocognitive decline gets significantly delayed when the 
MGd is used with WBRT.(56)  
A signiﬁcant delay in time to neurologic progression for patients treated 
with MGd with WBRT was found (P = 0.018, unadjusted). But In terms of 
survival (median, 5.2 months for MGd v 4.9 months for WBRT; P = .48) or 
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neurologic decline (median, 9.5 months for MGd v 8.3 months for WBRT;  
P = .95) no significant difference was found.  
Brown et al performed the study using memantine for prevention of 
cognitive dysfunction in patients on whole brain radiotherapy(57). It was a 
randomized, double-blind, placebo-controlled trial with memantine and 
placebo. Here the patients with brain metastasis on treatment WBRT receive 
either placebo or memantine (20 mg/d), within 3days of initiating radiotherapy. 
The study went on for 24 weeks and various neuropsychological assessments 
were done. Patients with malignancy diagnosed in last 5 years and visible mass 
on MRI were selected for study. KPS >70, no physical deterioration, Mini 
Mental State Exam (MMSE) score  > 18,  no chronic use of benzodiazepine 
and no drug abuse were some of the important eligibility criteria. Patients were 
randomized and received placebo or memantine.   
Patients were treated with 37.5 Gy of WBRT (15 fractions of 2.5 Gy) 
with memantine administration to treatment arm. Neuropsychological 
assessment was done at baseline and 8, 16, 24, and 52 weeks. 173 out of 508 
patients [34%] recruited for the study died in the 6 months course of treatment. 
Patients who completed the tests all the occasion were found to have longer 
duration of survival [median overall survival of 12.4] and better quality of 
living.  
HVLT on the patients showed that there was less decline in cognition 
with memantine (median decline of 0) compared to the placebo cases (median 
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decline of –0.90) after 24 weeks(57) which was statistically not significant with 
[P= 0.059]. But the result had less statistical power [35%] due to attrition. In 
contrast the memantine showed significant benefits compared to placebo in 
terms of HVLT-R Delayed Recognition (median decline 0 vs. –1, P=0.0149) at 
24 weeks. Similarly the MMSE scores (median decline 0 vs. –1, P=0.0093) 
also showed significant difference compared to placebo at 24 weeks. HVLT-R 
Delayed Recognition scores (median decline 0 vs. –0.715, P¼.0115) showed 
significant difference in favor of memantine at 24 weeks using standardized 
scores.  
The study showed significant decline occurring in terms of 
Neurocognition in placebo arm exposed exclusively to WBRT. At 3 months 
51.9% of the patients showed neurocognitive decline and it increased to 64.9% 
at 6 months. In contrast the neurocognitive decline was 43.7% and 53.8% in 
memantine treated patients at 3 months and 6 months respectively(57). The 
study thus showed that WBRT is associated with neurocognitive decline and 
usage of memantine resulted in better cognitive outcome.(57) The cognitive 
function improved over time as it delayed cognitive decline by reducing the 
rate of decline in executive function, memory and processing speed. 
Ping fang tsai (40) in his study on 40 patients performed hippocampal 
sparing WBRT. He used the Volumetric Modulated Arc Therapy (VMAT) with 
two full arcs and two non-coplanar partial arcs. With this technique he could 
deliver radiation specifically sparing the hippocampus. He performed 
neurocognitive assessment before and after 4 months of performing the WBRT. 
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Neurocognitive assessment scores were available for 24 patients after 4 
months. Among them, he showed that at there no significant decline in test 
scores. 
A study done by Onodea et al(58) actually showed the fluctuating 
course of the neurocognitive function after WBRT. In this prospective pilot 
study he enrolled 27 patients among which 20 received WBRT and rest  
7 received stereotactic irradiation. Neurocognitive data obtained at 4m, 8m and 
12 months. The study showed that there was a significant deterioration in 
delayed memory compared to the baseline (p = 0.04) at 4 months, and at 8 
months. But significant improvements were observed in immediate memory 
compared to the baseline (p = 0.008) and 4-months scores (p = 0.005). Strange 
result reported in this study was that at 12 months, the immediate memory 
scores had returned to the baseline. This pilot study had a very small population 
but gave an interesting result for further evaluation and research. 
        There are several studies that even claim that avoiding radiation 
exposure to hippocampus prevents neurocognitive decline .A study by Shin yin 
lin(23) performed on patients exposed the patients to hippocampal sparing 
whole radiotherapy.25 patients were enrolled for this study. After enrolling 
Patients they performed extensive investigations and then planned for WBRT. 
One important criterion was that patients didn’t have more than 3 tumor masses 
and none the masses were more than 4 cm in diameter. After performing MRI 
cases with tumor mass 5 mm around the hippocampus were excluded. 
Radiation was delivered as 30 fractions in 12 doses and neurocognitive 
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assessment was performed after 4 months and 12 months. They found that 
there is no significant drop in cognitive scores in tests. But the compliance at 4 
months for neurocognitive assessment was only 54% which was suggested to 
be due to patient related factors. Thus according to this study avoidance of 
radiation exposure to hippocampus can protect patient from neurocognitive 
impairment. 
Jing li (59)in their study showed the association of tumor shrinkage and 
neurocognitive function. They showed that the increase in tumor growth is 
associated with more neurocognitive decline than the exposure to WBRT(37). 
So they followed 135 patients and measured the neurocognitive function at 4 
months and 15 months. The analysis was done here based on the size of the 
indicator lesion and lesion volume reduction at 2 months was above or below 
the population median reduction of 45%.  
The results showed that good responders to radiation therapy had better 
scores in all the 8 neurocognitive assessment scales used in the study. The 
delay of neurocognitive function deterioration in good responders were noted 
with better scores in an executive function test Trail making B (131 days’ gain; 
P = 0.02), and the ﬁne motor coordination tests Pegboard NDH (110  days’gain; 
P = 0.02) and Pegboard DH (93days’ gain; P = 0.05).(59) But memory was 
found to have weaker association with tumor volume reduction with values still 
showing better preservation of memory with reduction in the volume of mass 
lesion.  
 35 
Results showed net gain of 61, 52 and 59 days for recall, recognition, 
and delayed recall, respectively. They showed that WBRT induced shrinkage 
of tumor mass gave survival benefit and preserved neurocognitive function. 
Disease progression is the key reason for poor survival in cancer patients. Here 
the patients who respond well to Whole brain radiotherapy have better control 
over their executive function and fine motor coordination but, there is still 
some deterioration in memory function that happens which gets masked by the 
improvement in symptoms obtained with reduction in tumor mass. 
If we look into the effect of WBRT on cognition in patients with 
primary CNS lymphoma(60) the study by Doolittle et al will share some 
insight. 80 participants took part in study. They were divided in to 4 groups and 
one of these groups was treated with WBRT+ chemo and other with 
methotrexate based regimens alone. Over next 2 years patients under went 
neuropsychological evaluation, quality of life assessment and MRI scans. 15 
out of 80 patients were treated with methotrexate followed by WBRT. Patients 
selected for the study were ones who had minimum 2 years of treatment and 
disease remission. Later neuropsychological assessment was done with 
Wechsler Adult Intelligence Scale—III Digit Span subtest [Digits Forward, 
Digits Backward], Trail Making Test and Brief Test of Attention, verbal 
memory (Hopkins Verbal Learning Test– Revised),motor skills with Grooved 
Pegboard Test.  Quality of life was tested with European Organization for 
Research and Treatment of Cancer (EORTC) QOL Questionnaire–30  
(QLQ-C30). results showed that patients treated with WBRT had lower 
 36 
cognitive performance. Patients on WBRT had a mean score 0.65 points (95% 
CI, 0.20–1.10; p 5 0.0051) lower compared to patients on 3 non-WBRT groups 
combined. But in terms of verbal memory there was no significant effect of 
WBRT recorded (p = 0.1246). 
  In terms of quality of life the patients scored poor in terms of physical, 
emotional and social functions. The above scores were found to associate with 
white matter abnormalities. This study may have small number of population 
size with median age of 58 years.(60) But it shows the improvement in verbal 
memory in patients exposed to methotrexate regimen with 45 Gy WBRT. 
After going through all these research a paper by Cole et al (61) 
analyzed the self reported cognitive outcome after radiation therapy for brain 
metastasis.50 adult patients were taken up for the study group and were treated 
with whole or partial irradiation . None of the patient in the therapy had past 
radiation therapy. Breast cancer patients without cranial involvement on 
adjuvant therapy were controls. Self reported cognitive ability was measured 6 
weeks, 3 months, and 6 months after irradiation. Neurocognitive status was 
measured using German questionnaires for self-perceived deficits in attention 
(FEDA) and subjectively experienced everyday memory performance (FEAG). 
Baseline data showed high degree of self perceived cognitive deficit in both 
groups.  
On statistical evaluation there was significance in group differences for 
the FEDA scales 2 and 3.(61) The results showed a significant increase in 
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fatigue and retardation of daily living activities (P=.002) and also decrease in 
motivation (P=.032) in the patients exposed to WBRT. The radiation exposure 
also caused an increase of attention deficits in the WBRT patients, but not in 
the Control Group.(61) The scores of distractibility and retardation of mental 
processes (P=.059) between the WBRT/partial RT and the controls were close 
to significance. Thus the study concluded by saying that self reported attention 
declined in patients treated with WBRT/ partial RT compared to controls. 
        Function have been reported in rats [15] in response to single [16] and 
fractionated [17, 18] WBRT. Additionally, deficits in spatial learning have 
been reported in mouse models [19, 20]. Our laboratory recently demonstrated 
that fractionated WBRT induces time-dependent learning and memory deficits 
in both the Barnes maze and active avoidance tasks [21]. Importantly, spatial 
learning was progressively impaired after WBRT as mice exhibited increased 
latency to the escape box and made more errors in the Barnes maze in the 
months following treatment. Despite extensive studies demonstrating the 
effects of WBRT on cognition in multiple species, the etiology of WBRT-
induced cognitive impairment remains poorly-understood. 
  In reviewing all these research articles we can get invaluable 
information about cognitive outcome of WBRT. WBRT is like a double edged 
sword with its multiple benefits and side effects.  Research has shown that it 
improved the survival of patients on WBRT by causing some degree of 
cognitive decline. Radiation exposure in children is associated with IQ decline 
which has been established in several follow up studies. There was a high 
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incidence of learning disabilities, academic failure with poor 
attention, memory and executive functions along with low intellectual 
level. Patients’ also scored poor in quality of life measure.(62) Higher doses of 
radiation had greater cognitive decline but still very little is known regarding 
their cognitive outcome. Further research is needed in this area to establish 
several unknown facts. 
Quality of life is measured as a part of several researches on WBRT(63). 
Quality of life of cancer patients depends on heterogenous factors. Various 
cancers related quality of life scales have been created giving varying 
results(63). Each scale takes different domains into consideration while 
measuring the quality of life. Functional Assessment of Cancer Therapy - Brain 
(FACT-BR) questionnaire is a popular scale to measure quality of life in 
disorders of brain. This scale uses 2 subscales namely, Functional Assessment 
of Cancer Therapy General (FACT-G) and the Brain Subscale. The FACT-G 
covers four primary QoL domains: Physical Well-Being (7 items), 
Social/Family Well Being (7 items), Emotional Well-Being (6 items); and 
Functional Well-Being (7 items).  
European Organization for Research and Treatment of Cancer Quality 
of Life Core Questionnaire (EORTC QLQ-C30) is another scale that is used by 
some studies to measure quality of life. It consists of 5 functional scales 
(physical, role, cognitive, emotional, and social) and 3 symptoms scales 
(fatigue, pain, and nausea and vomiting). EORTC QLQ-C30 concentrates more 
on social activities and family life, while the FACT-G mainly focuses on social 
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support and relationships. We in our study used 3 different scales concentrating 
on various aspects of life. 
The study by Sun et al(41) studied the quality of life of patients on 
WBRT for NSCLC. This study used the EORTC QLQ-C30 scale and BN 20 
for the assessment. After the study they found that there was no statistically 
significant decline in quality of life at end of 12 month follow up [P> 0.05].  
Jing li(11) in his study used the ADL [activities of daily living] and FACT-Br 
[Functional Assessment of Cancer Therapy-Brain-specific] for neurocognitive 
assessment of his patients on WBRT. He proved that quality of life in a patient 
can be correlated with neurocognitive decline seen in the previous visit. Thus 
neurocognitive decline is a predictor of the quality of life in near future. 
Another study by Gao et al (64) tries to assess the quality of life 
palliative WBRT patients and found again that the quality of life improved 
after the treatment with whole brain radiotherapy. This study basically utilized 
the health-related QOL (HRQOL) of patients with Brain metastasis. He 
selected 46 patients for this study and among them 35 were exclusively 
exposed to WBRT and 6 to WBRT + Chemotherapy other 5 to supportive care. 
The mean age of the sample was 52.6 years. The analysis showed that survival 
was 11.8±0.46 months for patients on WBRT, 11.75±1.00 months for patients 
on WBRT + Chemotherapy, and 3±0.79 months Supportive Care (P<0.01). The 
HRQOL scores of patients on Whole Brain Radiotherapy were 72.23±0.88 
(before therapy) and 78.49±0.87 (after therapy) (P<0.01). Thus study showed 
significant improvement in quality of life. But still the average survival in the 
study was only 11.8 months.(65) Thus several studies on the cancer patients 
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have shown that radiation therapy to the brain gives significant improvement in 
the quality of life. Hence it can be made as part of therapy for patients with 
brain metastasis. 
Radiotherapy procedure 
Whole brain radiotherapy was delivered using Radiotherapy device with 
cobalt 60 source.(66) The patient was put on supine position and radiation was 
delivered. The head of the patient was immobilized by thermoplastic masks. 
Right and left lateral position treatment was given on the same day with 
required dose, i.e. 1.5 Gy each to left and right side. Corticosteroids and 
mannitol were administered to the patients in the ward to prevent increased 
intra cranial tension due to brain edema. 
Whole brain radiotherapy treatment should have adequate coverage of 
all intracranial contents. It should be planned to entirely cover the entire cranial 
fosse and even the skull base. Beam arrangement is done in right and left 
lateral opposing fields. Shape of the field can be adjusted and radiation was 
applied. 
Dosage 
Standard dose of 30 Gy in 10 daily fractions or 20 Gy in 5 daily 
fractions is used. Any dose higher than 30 Gy in 10 fractions did not give 
further benefit in patients with brain metastasis. The Cochrane reviews on this 
area showed no further improvement with any altered dosage regimens in terms 
of survival, neurological outcome or quality of life or symptom control. 
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AIMS AND OBJECTIVES 
• To study the neurocognitive change that can occur due to whole brain 
radiotherapy. 
• To measure the MMSE, MoCA, HVLT, and Trail making test scores 
of patients on WBRT. 
• To study the quality of life of the whole brain radiotherapy patients 
using Katz ADL, LBADL and WHO QOL Bref scales. 
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METHODOLOGY 
The study was conducted in department of radiation oncology, Barnard 
institute of radiology, Madras Medical College, Chennai. The thesis abstract 
was presented before the institution ethics committee and approval was 
obtained. The study was done from February 2017 to august 2017.  Patients 
suffering from brain metastasis were chosen for study based on inclusion and 
exclusion criteria. A detailed informed consent was taken from the patient and 
then recruited for our study. Initially their IQ was measured with BKT. Later 
whole brain radiotherapy sessions were conducted and relevant data was 
collected for study. The relevant scales were applied thrice i.e. immediately 
after WBRT, 3 months and after 6 months. The collected data were analyzed 
using SPSS package and necessary results obtained. 
Inclusion criteria 
• Patients undergoing whole brain radiotherapy at, Department of 
Radiation oncology, Madras Medical College, Chennai 
• Age 40 to 70 
• Ability to give informed consent 
• Karnofsky performance status  >70. 
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Exclusion criteria 
 Mental retardation (IQ< 70) 
 KPS <70 
 Patients not giving consent 
 Known major psychiatric illness 
 Patients on chemotherapy 
 Past therapeutic radiation exposure to brain 
 
 
 
Neurocognitive assessment tools 
1)  MMSE 
2) Montreal cognitive assessment test 
3) Hopkins verbal learning test 
4) Activity of Daily Living Scale 
5) Binet Kamath Test 
6) WHO QOL 
0 months
• Neurocognitive 
assessment
• Quality of life 
assessment
• 43 cases
3 months
• Neurocognitive 
assessment
• Quality of life 
assessment
• 40 cases reviewed
• 3 expired
6 months
• Neurocognitive 
assessment
• Quality of life 
assessment
• 40 cases reviewed
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Scales 
Mini mental status Examination (67) 
MMSE or Folstein test is an extensively used screening tool for 
cognitive assessment.  It is a highly trusted scale due to good test – retest 
reliability. MMSE is highly sensitive and specific test for dementia and 
cognitive impairment. Occasionally the scale has been criticized to be less 
useful when the patient is highly impaired with Neurocognition.  
(68) This scale consists of following components. 
• Orientation to time- 5 [year, season, date, day , month] 
• Orientation to place-5 [present, state, country, town, hospital, floor] 
• Registration-3 [repeat 3 unrelated objects ] 
• Attention and calculation-5 [serial subtraction of  100, ] 
• Recall-3 [ recall the words registered] 
• Language-2 [name pencil and watch] 
• Repetition-1 [speak back the phrase] 
• Complex commands-6 [draw the complex figure shown] 
Montreal cognitive assessment test (69) 
MoCA was created in 1996 by Ziad Nasreddine. It tests orientation, 
short term memory, executive function, language abilities, attention, 
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visuospatial abilities. Unique to MoCA is that it tests clock drawing test and 
trail making test 2 in it. The benefit of MoCA is its simplicity of 
administration, reliability and accuracy in detecting dementia and cognitive 
impairment.(70)  
• Visuospatial / executive- 5 [trail making, draw a cube, clock drawing] 
• Naming-3 [name 3 animal from picture sown] 
• Memory [read list of 5 objects] 
• Attention-6 [read  list of digits, tap hand when specific letter id told, 
serial subtraction] 
• Language-3 [repetition and fluency] 
• Abstraction-2 [similarities between objects] 
• Delayed recall-5 [recall the 5 objects told in memory section] 
• Orientation-6 [date, month, year, day, place, city] 
Hopkins verbal learning test(71) 
It is a test of verbal learning and memory. It is a valid test for encoding 
retrieval and retention. It consists of free recall of 12 items from a semantically 
categorized list done in 3 trials. Later, followed by yes / no recognition. The 6 
lists are formulated in such a way that all yield similar result on a particular 
patient.(72) 
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Test consists of 12 items word list having 4 words from 3 different 
semantic categories. The list read out slowly one word every 2 seconds. Then 
patients’ free recall is checked in 3 trials. Later 24 word list is read out 
including the above 12 words and patient is asked to tell yes to which words 
appeared in the 12 word list no to the words that didn’t. 12 extra words that are 
read out are distracters or unrelated words. This test is unique in terms of the 
duration needed for its administration as it needs 10 min to administer. It is 
even easy to administer in demented and debilitated patients. 
Trail making test (73) 
Trail making test was derived from Taylor number series test. This test 
was later revised into present form and included in Halstead Reitan 
neuropsychological battery. The 2 varieties include TMT A and TMT B. Part A 
consists of numbers in series and the participant needs to connect them 
sequentially. In contrast, Part B requires the participant to connect the numbers 
and alphabets alternatively in sequence. Part A basically deals with motor 
speed and visual search/ attention. Part B mainly deals with higher order 
cognition, mental flexibility and executive control. The performance in TMT is 
a good indicator of intelligence and it is also said to be sensitive marker of 
neurological impairment. 
Scoring   
Trail A: Average- 29 seconds, Deficient if > 78 seconds, Rule of 
Thumb- Most in 90 seconds. 
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Trail B: Average- 75 seconds, Deficient if > 273, Rule of Thumb- Most 
in 3 minutes 
Katz activities of daily living.(74) 
The patients on WBRT often are physically debilitated. Hence this scale 
was used measure the daily living difficulties. Katz instrument was devised in 
1970 and has been widely used since then mainly for assessing patients with 
stroke. This scale helps to assess the daily living abilities of the patient. A fully 
functional patient gets a score of 6, while 4 implies moderate impairment and 2 
severely impaired. The instrument is found to be highly reliable with reliability 
index of 0.87 to 0.94.(75) With each factor examiner checks if the patient is 
independent or dependant. 
• Bathing 
• Dressing 
• Toileting 
• Transferring 
• Continence 
• Feeding 
The Lawton Instrumental Activities of Daily Living (IADL) Scale(76) 
IADL is a good instrument to measure independent living skills. These 
skills are considered more complex than the basic activities of daily living as 
measured by the Katz Index of ADLs. This scale is considered to be very 
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useful for measuring the level of functioning of a person and to assess the 
improvement or deterioration over time. This test consists of 8 domains. They 
include, using the telephone, shopping, preparing food, and housekeeping, 
doing laundry, using transportation, handling medications and handling 
finances. The inter rater reliability was 0.85. The test is easy to administer as it 
can be done in 10 min. Only limitation is that the test is self report of the 
participant. 
WHO QOL Bref(77) 
WHO QOL Bref is one of the internationally acclaimed and validated 
scales for measurement of quality of life. It was thoroughly researched in 
various countries in a multinational study and standardized. The scale consists 
of questions from various domains or areas of life and scored by the patient 
accordingly.(78) 
The scale basically has 4 domains 
• Physical 
• Psychological  
• Social 
• Environmental 
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By measuring the scores in all the areas scores are found which gives an 
estimate of quality of life. 
1.  Physical health Activities of daily living   
Dependence on medicinal substances and medical 
aids  
Energy and fatigue  
Mobility  
Pain and discomfort  
Sleep and rest  
Work Capacity 
2.  Psychological Bodily image and appearance  
Negative feelings  
Positive feelings  
Self-esteem Spirituality / Religion / Personal 
beliefs  
Thinking, learning, memory and concentration 
3.  Social relationship Personal relationships 
 Social support 
 Sexual activity 
4.  Environment Financial resources Freedom, physical safety and 
security Health and social care: accessibility and 
quality Home environment Opportunities for 
acquiring new information and skills Participation 
in and opportunities for recreation  / leisure 
activities Physical environment (pollution / noise / 
traffic / climate) Transport 
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STATISTICS 
Analysis of repeated measure(79) 
The term “repeated measure” refers to multiple responses taken in the 
sequence on the same experimental unit. Usually the responses are taken over 
time. The objective of repeated measure data analysis is to examine and 
compare response trends over time. Here multiple measurements are made on 
the same experimental units over a period of time. (80) Such data are called 
repeated measures 
The data of the analysis of repeated measures are analyzed in several 
ways using, 
• Separate analysis at each time unit 
• Univariate analysis of variance 
• Univariate and multivariate analysis of time contrast variables. 
• Mixed model methodology. 
Analysis at each time points measures treatment effect at each individual 
time points but makes no comparison between times. Here no inference can be 
drawn about trend over time. 
Univariate analysis of variance is historically applied to repeatedly 
measure data that makes comparison between times. It treats the data as if they 
were from split part design. So it is also called split plot in time analysis. 
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Repeated measure analysis needs special attention into covariance structure as 
it deals with data in sequence. Ignoring or excluding the covariance will give 
incorrect results. Then mixed analysis procedure is used which has 2 steps.(81)  
- Model the covariance structure.  
- Analyze the time trends for treatment by analyzing and comparing 
the means. 
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RESULTS 
The study was done at Institute of radiation oncology, Barnard institute 
of radiology at Madras medical college, Chennai. Patients were selected from 
outpatient department who had come with brain metastasis. Initially full 
physical examination was done to assess for the current physical status. CT and 
MRI scan were taken to confirm the cerebral metastasis and exactly localize the 
tumor location and extent. In our study we concentrated exclusively on the 
neurocognitive effects of WBRT on brain metastasis patients. 
A total of 43 subjects were selected for the study and an informed consent was 
obtained. Study population consisted of 22 males and 21 females. 
 
Table 1, Study population 
The patients had different education levels. 2.3% of the population was 
illiterate but with IQ more than 70. 30 % of the population had less than 5 years 
of schooling. Majority of the population i.e. 46.5% of the population had 6 to 
10 yrs of schooling. Rest 20.9% had more than 10yr of schooling. 
Male 22 51.2 
Female 21 48.8 
total 43 100% 
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Figure 3, Literacy level 
Our study subjects were mainly from lower socioeconomic background. 
Majority of them worked as coolie or daily wage laborers. Farmers and 
businessmen were other important members in the group. Females were mainly 
homemakers. 
In terms of socioeconomic status, majority of population were living on 
less than 5000 rupee income per month. 7 of our subjects had no income for 
themselves.20 patients had less than 1000rs income. So total of 62% of the 
patients lived on less than 1000 rs per month. 
 
 
Education
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Pre uniuversity
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Figure 4, Occupation level 
 
Figure 5, Population income 
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Figure 6, Binet kamath IQ test score levels 
The intelligence level of the patient plays an important role in the ability 
of the patient to participate in the study. Hence Binet Kamath intelligence 
assessment test was used to measure the Intelligence quotients. All the patients 
had IQ >70. Once the patient was selected for the study immediately IQ was 
measured and later his assessment with CT and MRI was continued. 
The most important factor in any whole brain radiation therapy is the 
type of the primary tumor. Type of tumor helps in understanding the sensitivity 
of the tumor to radiation and indirectly helps in estimating the prognosis. 
Majority of the patients i.e. more than 50% patients in our study had lung 
cancer. Most of the patients had small cell lung carcinoma and few had Non 
small cell variety. Next major variety was breast cancer and was almost 
exclusively found in females. Melanocytoma and renal cell carcinoma are 2 
rare varieties found as metastasis to brain. 
BKT IQ assessment scores 
70-74
75-79
80-84
85-89
90-95
96-99
 56 
 
Figure 7, Primary sites of brain metastasis 
After gathering all the particulars of the patient then all the 
neuropsychological assessment scales were applied along with quality of life 
assessment scales. Later patient was treated with 30Gy of radiation in 10 
fractions over 10 days. During the first 2 months of follow up 3 patients 
expired and hence were not included in further analysis. After 3 months and 6 
month all scales were applied and assessment scores were collected. Later 
statistical analysis was done to get the required results.  
Time 1 or [T1] = 0 month 
Time 2 or [T2] = 3 months 
Time 3 or [T3] = 6 months 
 
Primary sites of tumor
Adenocarcinoma
Breast cancer
Melanocytoma
Oesophageal carcinoma
Renal cell carcinoma
Lung cancer
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 Mean SD n 
T1 MMSE 
 
20.23 5.181 40 
T2 MMSE 19.90 6.698 40 
T3 MMSE 18.05 5.588 40 
 
Table 2 MMSE means and standard deviation at 0,3, 6 months 
We compared the various scores obtained at 3 different time points 
using analysis of repeated measures and obtained following results. 
MMSE 
Mean 
Difference 
(I-J) 
Std. 
Error Sig 
95% Confidence 
Interval for 
Difference 
Lower 
Bound 
Upper 
Bound 
T1 
T2 .325 .528 1.000 -.996 1.646 
T3 2.175* .345 .000 1.312 3.038 
T 2 
T1 -.325 .528 1.000 -1.646 .996 
T3 1.850* .579 .008 .401 3.299 
T 3 
T1 *-2.175* .345 .000 -3.038 -1.312 
T2 -1.850 .579 .008 -3.299 -.401 
 
Table 3, MMSE assessment results 
 
After the analysis we found that MMSE scores had dropped in 3 and 6 
months. The analysis found that there was significant drop from T1 to T3 
[p=0.000] and from T2 to T3 [p=0.008]. So the MMSE score is found to drop 
significantly by end of 6 months due to radiation exposure [P < 0.05]. 
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Montreal 
cognitive 
assessment 
Mean 
Difference 
(I-J) 
Std. 
Error Sig 
95% Confidence 
Interval for 
Difference 
Lower 
Bound 
Upper 
Bound 
T1 
T2 -.375 .642 1.000 -1.982 1.232 
T3 2.875* .565 .000 1.461 4.289 
T 2 
T1 .375 .642 1.000 -1.232 1.982 
T3 3.250* .400 .000 2.250 4.250 
T 3 
T1 -2.875* .565 .000 -4.289 -1.461 
T2 -3.250* .400 .000 -4.250 -2.250 
 
Table 4, Montreal cognitive assessment results at 0,3,6 months 
 
 Time 1 Time  2 Time 3 
MCog assessment 19.20±5.25 18.08±2.269 15.95±5.71 
Visuospatial 2.85±1.37 18.83±7.00 2.68±1.385 
Naming 2.80±0.464 2.65±0.700 2.68±0.572 
Attention 4.25±1.48 4.10±1.823 3.08±1.526 
Language 1.33±0.917 1.53±1.037 1.13±0.966 
Abstract 1.13±0.563 0.98±0.733 0.9±0.563 
Delayed recall 2.70±0.791 2.63±1.25 1.95±0.714 
Orientation 4.18±1.412 4.05±1.632 3.58±1.43 
 
Table 5, MoCA results, with individual score analysis 
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We applied another assessment scale for Neurocognition on patient i.e. 
Montreal cognitive assessment scale. This scale also showed that there was 
significant decline in Neurocognition from T1:T3 and T2: T3.  Mean was 
found to drop from T1 to T2 but was not found to be significant. So there is 
further evidence to prove the cognitive decline during first 6 months of 
radiotherapy. 
For further detail in understanding the area of cognitive decline we even 
compared each components of MoCA. With pair wise comparison so we found 
that there was decline in mean scores of visuospatial function happening from 
T1 toT3 but it was not found to be significant. In terms of naming skills too 
there was significant decline in cognitive skills. 
Attention span was found to drop significantly from T1 to T3 and T2 to 
T3. Hence radiation has its negative role in reducing the attention. 
Language skills are also found to fall found to all over 6 months. The 
mean language score at T1 which was 1.33±0.917 has dropped to 1.13±0.966. 
When comparing the scores between 2 intervals we find that the T2:T3 scores 
has a significant drop in scores with a difference of 0.400 and (P=0.003). 
Abstract scores have dropped significantly fromT1 to T3 according 
MoCA scores. Even the delayed recall and orientation have shown significant 
decline over 6 months. 
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Figure 8, MoCA invidual assessment results. 
Comparison of individual components of MoCA gave following results, 
Table 6 Visuospatial skill 
Visuospatial T1 : T2 T1 : T3 T2 : T3 
Difference -0.025 0.175 0.200 
Standard error 0.162 0.123 0.144 
significance 1.000 0.493 0.519 
 
Table 7 Naming 
Naming T1 : T2 T1 : T3 T2 : T3 
Difference 0.15 0.125 -0.025 
Standard error 0.067 0.053 0.044 
significance 0.096 0.070 1.000 
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Visuospatial 
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Attention 
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6 months
3 months
0 months
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Table 8 Attention 
Attention T1 : T2 T1 : T3 T2 : T3 
Difference 0.150 1.175 1.025 
Standard error 0.216 0.160 0.219 
significance 1.000 0.000 0.000 
 
Table 9 Language 
Language T1 : T2 T1 : T3 T2 : T3 
Difference -0.200 0.200 0.400 
Standard error 0.109 0.082 0.112 
significance 0.219 0.057 0.003 
 
Table 10 Abstract 
Abstract T1 : T2 T1 : T3 T2 : T3 
Difference 0.150 0.225 0.075 
Standard error 0.076 0.076 0.083 
significance 0.170 0.015 1.000 
 
Table 11 Delayed recall 
Delayed recall T1 : T2 T1 : T3 T2 : T3 
Difference 0.075 0.750 0.675 
Standard error 0.187 0.106 0.154 
significance 1.000 0.000 0.000 
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Table 12 Orientation 
Orientation T1 : T2 T1 : T3 T2 : T3 
Difference 0.125 0.600 0.475 
Standard error 0.144 0.123 0.168 
significance 1.000 0.000 0.022 
 
Table 13, Hopkins verbal learning test trial 1 results 
Trial 1 Time 1 Time2 Time 3 
HVLT form 1 3.40±0.955 3.25±0.899 2.80±0.758 
HVLT form 2 3.33±1.16 3.35±0.893 3.03±0.862 
HVLT form 3 3.35±1.1 3.25±0.981 2.93±0.944 
HVLT form 4 3.45±1.39 3.35±1.027 2.98±0.80 
HVLT form 5 3.23±0.920 3.43±0.903 3.10±0.871 
HVLT form 6 3.45±1.39 3.35±1.027 2.98±0.80 
 
Table 14, Hopkins verbal leaning test trial 2 results 
Trial 2 Time 1 Time2 Time 3 
HVLT form 1 4.10±1.057 4.28±1.198 3.83±1.13 
HVLT form 2 4.15 ± 1.29 4.00± 1.01 3.63± 1.07 
HVLT form 3 4.20±1.137 4.18±1.13 3.68±1.023 
HVLT form 4 4.20±1.265 4.15±1.051 3.70±1.181 
HVLT form 5 4.10±1.057 4.28±1.198 3.83±1.13 
HVLT form 6 4.20±1.265 4.18±1.13 3.68±1.023 
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Table 15, Hopkins verbal learning test trial 3 results 
Trial 3 Time 1 Time2 Time 3 
HVLT form 1 
 
5.13±1.285 5.25±1.193 4.78±1.1187 
HVLT form 2 5.28±1.71 5.20±1.203 4.58±1.259 
HVLT form 3 5.28±1.601 5.13±1.265 4.60±1.257 
HVLT form 4 5.35±1.51 5.23±1.33 4.68±1.207 
HVLT form 5 5.13±1.285 5.25±1.193 4.78±1.187 
HVLT form 6 5.13 ±1.36 5.15±1.16 4.68±1.17 
 
Table 16, Trail making test part A Results 
Trail making test 
part A 
 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval for 
Difference 
Lower 
Bound 
Upper 
Bound 
T 1 
 
T 2 -1.275 2.099 1.000 -6.525 3.975 
T 3 -8.425* 2.241 .002 -14.032 -2.818 
T 2 T 1 1.275 2.099 1.000 -3.975 6.525 
T 3 -7.150* 1.619 .000 -11.201 -3.099 
T 3 T 1 8.425* 2.241 .002 2.818 14.032 
T 2 7.150* 1.619 .000 3.099 11.201 
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Table 37, Trail making test part B results 
Trail making  
test part B 
Mean 
Difference 
(I-J) 
Std. 
Error Sig 
95% Confidence 
Interval for Difference 
Lower 
Bound 
Upper 
Bound 
T1 
T 2 -1.850 2.251 1.000 -7.481 3.781 
T 3 -13.350* 4.944 .031 -25.719 -.981 
T 2 
T 1 1.850 2.251 1.000 -3.781 7.481 
T 3 -11.500* 3.913 .017 -21.289 -1.711 
T 3 
T 1 13.350* 4.944 .031 .981 25.719 
T 2 11.500* 3.913 .017 1.711 21.289 
 
We also analyzed the quality of life of the patients undergoing the 
WBRT. On applying the Katz activities of daily living scale and Lawton body 
instruments of daily living we could find the ability of the patient to perform 
daily activities. Next we applied the WHO QOL Bref scale to measure the 
patient’s quality of life in various domains. 
Table 4, Quality of life anlysis results 
 Time 1 Time 2 Time3 
Katz ADL 4.43±1.6 3.53±1.2 2.73±1.10 
Lawton body 
instrument 
3.58±1.52 2.8±0.99 1.8±0.883 
WHO QOL  
Domain 1 raw score 
19.13±2.83 
 
17.03±2.006 14.90±1.37 
WHO QOL  
Domain 2 raw score 
16.05±2.160 14.30±2.078 12.70±1.285 
WHO QOL  
Domain 3 raw score 
8.25±1.75 6.53±0.987 5.38±1.148 
WHO QOL  
Domain 4 raw score 
21.45±2.94 18.08±2.269 15.33±2.22 
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We later compared the scores of quality of life of the patients in three 
different time periods.  
Table 19, Quality of life anlysis results 
Katz activities of 
daily living 
Mean 
Difference 
(I-J) 
Std. 
Error Sig 
95% Confidence 
Interval for 
Difference 
Lower 
Bound 
Upper 
Bound 
1 
2 .900* .234 .001 .314 1.486 
3 1.700* .251 .000 1.072 2.328 
2 
1 -.900* .234 .001 -1.486 -.314 
3 .800* .187 .000 .333 1.267 
3 
1 -1.700* .251 .000 -2.328 -1.072 
2 -.800* .187 .000 -1.267 -.333 
 
Table 20, Lawton body activities of daily living scale results 
 
 LBADL 
Mean 
Difference 
(I-J) 
Std. 
Error Sig. 
95% Confidence 
Interval for 
Difference 
Lower 
Bound 
Upper 
Bound 
1 
2 .775* .201 .001 .272 1.278 
3 1.775* .225 .000 1.212 2.338 
2 
1 -.775* .201 .001 -1.278 -.272 
3 1.000* .107 .000 .731 1.269 
3 
1 -1.775* .225 .000 -2.338 -1.212 
2 -1.000* .107 .000 -1.269 -.731 
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Table 51, WHO QOL Bref domain 1 raw scale analysis 
Domain 1 T1 : T2 T1 : T3 T2 : T3 
Difference 2.100 4.225 2.125 
Standard error 0.347 0.501 0.330 
significance 0.000 0.000 0.000 
 
Table 62, WHO domain 2 raw scale analysis 
Domain 2 T1 : T2 T1 : T3 T2 : T3 
Difference 1.750 3.350 1.600 
Standard error 0.370 0.368 0.295 
significance 0.000 0.000 0.000 
 
Table 73, WHO domain 3 raw score analysis 
Domain 3 T1 : T2 T1 : T3 T2 : T3 
Difference 1.725 2.875 1.150 
Standard error 0.235 0.306 0.174 
significance 0.000 0.000 0.000 
 
Table 84, WHO domain 4 raw score analysis 
 
Domain 4 T1 : T2 T1 : T3 T2 : T3 
Difference 3.375 6.125 2.750 
Standard error 0.437 0.502 0.370 
significance 0.000 0.000 0.000 
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Figure 9, Pattern of domain scores over, 0, 3, 6 months 
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DISCUSSION 
WBRT is a unique therapy for brain metastasis. Several randomized and 
non randomized studies have been conducted in these cases but have yielded 
unequivocal results. To date there are very few studies that measure the effect 
of WBRT on neurocognitive function and quality of life.(82) These studies 
examined patients with varieties of malignancies in different age groups by 
exposing them to different radiation regimens. Thus, we have a whole set of 
research with different findings and results(82).. 
  In our study we analyzed data gathered from many patients with brain 
metastasis who were treated with WBRT. We tried to understand the 
neurocognitive changes that happen over 6 months. 
  Our study was conducted at a tertiary care hospital with patients chosen 
for WBRT. The study was done in one of the largest apex institute and the 
sample can fairly represent the population in the locality. 22 males and 21 
females were recruited for our study and among them 3 expired and were not 
available for total 6 month follow up. 
In our study the median age of the population was 58 years which was 
close the sample taken in international studies. Median age was 59 in the study 
conducted Brown et al(57) with majority among them being females. 
  The sample consisted of fairly equal number of males and females thus 
covering the major cancers affecting both the sex. The major cancer in our 
patients was lung cancer which consisted of both small cell and non small cell 
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lung cancers. These numbers went on with the numbers obtained in the 
international studies(3). Second highest in incidence we observed in the study 
was the breast cancer commonly seen. 
The occupation wise majority of our population was daily wage 
workers. Their work place exposure to carcinogens may be a reason for 
increased incidence of tumors and in turn brain metastasis which needs further 
exploration. Income wise categorization was also done on our patients and we 
found that majority of our patients were from low socioeconomic level and had 
income less than 5000 per month. 
Binet Kamath Test was the intelligence assessment test applied to see if 
the patient could go through the assessment. Patients with IQ < 70 where 
excluded from the study in the first place. There are studies done on the 
children on WBRT showing the decline in IQ scores with radiation 
exposure.(83) But all the studies show decline in IQ results occurring in due 
course at least few years after the treatment. The study by Annett et al 
(84)showed that the trajectory of decline in neuropsychological functioning, 
specifically verbal IQ. The neuropsychological impact of WBRT was evident 
only at 48 months and hence they suggested long term follow up. 
Mini Mental Status Examination 
MMSE is an important scale for assessing Neurocognition. Its 
importance is brought out in a study by Murray et al(38) which tried to prove 
its significance in patients on WBRT. We used the same scale in our study to 
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observe some interesting findings.  Our MMSE scores showed the drop in the 
neurocognitive scores occurring over 6 months (p=0.003). This was in 
accordance with many of the research that had happened before. Several 
authors have studied the MMSE scores in different settings and were able to 
estimate the outcome.  
As mentioned in our literature review, Meta analysis by Sun et al(41) 
showed significant decline in Neurocognition over months. Similarly study by 
Regine et al(37) and Murray et al followed the study population [MMSE scores 
28 to 30] over 2 and 3 months in 29% of cases. They concluded that the drop in 
MMSE is mainly due to poorly controlled metastasis and higher stages of 
tumor. So our MMSE decline goes on with many other international studies 
done in similar setup. When comparing the MMSE scores in 3 different times 
(0, 3, 6 month) the statistics again gave us significant decline over 6 months. 
Exposure to radiation in WBRT is associated with significant neuronal damage 
and altered neuronal functioning which has led to drop in MMSE scores. 
Meyers(56) and brown study made a significant study with Motexafin 
Gadolinium in Whole brain radiotherapy and showed some important findings. 
Their phase 3 study with 401 patients showed that almost 90.5% of their cases 
had neurocognitive decline at baseline. Among them 42.4% had decline in at 
least 4 or more areas. 
In case of severe impairment in cognition the MMSE scale is debatable 
with its sensitivity as demonstrated by Meyers and Wefel(14). Study by Olson 
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et al (85)showed that MoCA is superior in identifying the cognitive decline in 
patients than MMSE. His study compared MMSE and MoCA and proved 
that(85) MoCA identified 80% of the cases while MMSE found just 30 
with[P=0.0001]. Hence we went on to apply a more specific and sensitive 
assessment scale to our patients. 
Montreal Cognitive Assessment scale is another neurocognitive scale 
used on our patients to demonstrate the effect of the radiation exposure. Our 
study with patients on WBRT showed a decline in MoCA neurocognitive 
scores over 6 months (p=0.000). Hence the MoCA scores showed significant 
results in demonstrating decline in cognitive function. We went to further 
analyze each scores obtained in various domains of the MoCA.  
 Hopkins Verbal Learning Test [HVLT] 
Hopkins Verbal Learning Test is a verbal learning test which measures 
the new learning ability. It has high reliability and repeatability for measuring 
verbal learning and memory. This test is found to be highly sensitive and 
specific for various dementias and cognitive impairment. In Our study HVLT 
applied on the patients showed declining scores over 6 months. Each of the 6 
forms was applied with 3 trials each time over 0, 3 and 6 months. We found 
that on comparing the results of each sitting the score declined and hence 
verbal memory deteriorated significantly. The study Sun et al (41) was also 
depicting the result similar to our study in saying that HVLT results dropped 
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significantly due to exposure of WBRT. The initial 3 months of results showed 
p=0.001 which was close to the results obtained in our study. 
Similarly, the study  by Meyers et al(56) was also significant in proving 
the effect of radiation on the verbal learning ability of the patients. After 4 
months of follow up of these patients they found drastic decline in neuro 
cognitive scores basically memory function .In 12 months the HVLT showed 
significant decline among 48% of the patients. Overall the poor responders to 
therapy showed decline in all areas with fall in median score in 8 months. 
[HVLT recognition p= 0.0011, HVLT recall p = 0.0018, HVLT delayed recall 
p= 0.0377] 
From the above results with respect to HVLT we can infer that verbal 
learning shows significant decline due to exposure to whole brain radiation.  
Trail making test  
Trail making test is used a part of assessment of visual attention and task 
shifting. The test can provide information about visual search speed, scanning, 
speed of processing, mental flexibility, as well as executive functioning. 
A study on  trail making test done by Grosshans et al(87) used trail 
making test as a part of neurocognitive assessment showed that Trail Making 
Test B score[p=0.001] dropped due to WBRT. the study by Meyers et al(56) 
used trail making test and showed impairment in 44% of its subjects. Using the 
cox model they showed that there was a significant decline in Trail Making 
Test B scores with p=0.022. When they made a comparison with the indicator 
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lesion volume they again found a correlation with trail making result scores [p= 
0.001].but there was no correlation with the number of tumor masses. Our 
study our used the trail making test part A and part B on the patients. With 3 
month of follow up of our patients we did not find a significant decline in 
scores. But on 6 month follow up there was a significant decline in both trail 
making test part A and part B. Even in terms of trail making test our results go 
on with some of the standard studies done elsewhere. Thus we found a 
significant deficit occurring in our patients after exposure to whole brain 
radiotherapy. 
Quality of life assessment 
“Katz activities of daily living’’ was used in our study to basically 
measure the daily activities of the patients on WBRT. Often the patients on 
WBRT will be debilitated and hence a scale covering basic activities will give 
a picture on the real life status of these people. In our study this Katz scores are 
found to drop significantly over 6 months. We compared the individual scores 
measured at 3 settings and patient’s activity level was found to drop at each 
settings. One thing we could conclude is that with the exposure to WBRT 
participants become more debilitated and restricted in their daily activities. 
Since Katz score measure 6 areas of one’s life we also used Lawton 
body ADL scale to get some added information. Even with this scale the, we 
found to have reduced quality of life over 6 months. 
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 As the above scales cover most basic of the daily life activities we used WHO 
QOL Bref to measure the QOL in other domains. Literature did not reveal any 
study that used WHO QOL scale to measure the quality of life of patients on 
WBRT for brain metastasis. They preferred the QOL for brain damage and 
other scales in routine research. Our study revealed that the patients had 
decrease in quality of life in all domains over 6 Months. When we compared 
the individual scores at 3 durations still we found significant decrease 
happening as disease progress. In contrast a study by Tang et al(88) on  
radiation induced brain injury showed similar decline in QOL over  4 month to 
6 months. In the past research several studies tried to estimate the quality of life 
and gave varying results. Most studies used overall survival and local tumor 
control as one the end point.  
In the present day due to the developments in the treatment modalities 
the overall survival of the cancer patients has increased. Due to this the 
knowledge of quality of life and its management is absolutely necessary. The 
longer the patient survives with metastatic disease, the better systemic therapy 
and palliative care is necessary. Neurocognitive function plays an important 
role in QOL of the patient. The present treatment decisions are at times taken 
based on better quality of life even at the cost of survival benefits. The 
measurement of quality of life in cancer patients is difficult as loss of patients 
is a common entity often due to death, debility or poor motivation. Karnofsky 
Performance Status (KPS) is one of the measurement tools often used in 
radiotherapy literature to assess the ability of the patient to undergo certain 
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procedure. But, it is poor in measuring the cognitive abilities of the patient. 
KPS is said to have poor reliability, validity and inter rater reliability of 29%. 
The study by Gao et al (64) as discussed showed improvement in quality 
of life according to HRQOL scale. This was in contrast to the values obtained 
in our study because the mean age of the population in our study was 57.81 
years and our study used different scales to measure the quality of living. 
Another important difference would be that our study considered a group of 
patients with variety of primaries whereas the study by Gao et al(64) basically 
studied on the patients having non small cell lung cancer. 
We analyzed the whole lot of data obtained in our study and understood 
cognitive changes happening among our patients. Radiation damage occurs due 
to a complex and dynamic interaction of various mechanisms. It ranges from 
changes in neurotransmitters to cell death. WBRT causes multiple side effects; 
still according to research it is proved to be effective in increasing the survival 
of the patients. 
The stereotactic radio surgery is the latest development in the treatment 
of brain tumors. By focusing the calculated amount of radiation a specified 
focus this process give higher radiation exposure to the tumor mass. Meanwhile 
it also counters the radiation exposure to normal brain tissue. Non-randomized 
studies on STEREOTACTIC RADIOSURGERY alone in patients with four or 
more brain metastases have shown that the overall survival is comparable to 
WBRT. But the greatest problem with STEREOTACTIC RADIOSURGERY is 
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the high chance of tumor recurrence(89). This reason has maintained the 
WBRT in a superior position compared to STEREOTACTIC 
RADIOSURGERY. 
Other newer advances in the field include the Hippocampal sparing 
WBRT. It is a technique where the radiation exposure to the hippocampal stem 
cell compartment is avoided using intensity modulated radiotherapy 
(IMRT)(90). Here the sub granular zone of the hippocampus is exposed to 
lesser radiation compared to rest of the brain which receives normal WBRT. 
RTOG-0933 developed the guidelines for Hippocampal sparing WBRT where 
the dose to 100% of hippocampus was limited to 9 Gray (Gy) with a maximum 
dose to the hippocampus limited to 16 Gy. The rest of the brain parenchyma 
receives a dose of 30 Gy in 10 fractions(90). Neurocognitive assessment was 
done using HVLT showed only 7 % decline in scores compared to WBRT 
which showed 30% decline [p=0.0003]. But other research also warns of the 
high chances of tumor recurrence. 
  Ghia et al(91) studied the use of intensity-modulated radiotherapy in the 
vicinity of the tumor mass. They showed that 5 mm remains an acceptable 
distance from the hippocampus were a tumor mass can be targeted with 
radiation causing minimal effect on cognition. 
Composite tomotherapy with WBRT has been a new research area.(92) 
It has a benefit of providing a homogeneous whole brain dose distribution 
equivalent to conventional WBRT. The procedure also provides radio 
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surgically-equivalent dose distributions to individual metastases and 
hippocampal avoidance of radiation exposure. 
In the latest research the American Society for Radiation Oncology 
(ASTRO) recommended the use of WBRT along with SRS in their ‘choose 
wisely campaign’. The main reason for advocating this procedure was the 
cognitive decline and poor QOL associated with WBRT. They suggest that 
WBRT should be used only for leptomeningeal disease and multiple large brain 
metastases not manageable with SRS. At present the use of WBRT on patients 
undergoing surgery still questionable. Some specialists have started to use 
stereotactic radio surgery on the surgical cavity and routinely follow up 
radiologically. 
Neuroprotection strategies 
A set of studies have developed Neuroprotection strategies with WBRT 
using pharmacological means(90). They include the use of PPARα 25, rennin 
angiotensin system blockers, Experimental thalidomide, and motexafin 
gadolinium(93). The use of agents commonly used in the treatment of 
Alzheimer’s disease, including donepezil, memantine ,methylphenidate and 
alpha-tocopherol,  has been suggested(18). a study conducted in Hong Kong 
compared Vitamin E against placebo in treating temporal lobe radio necrosis 
and found improvement in global cognition, memory and executive 
function(94). Patients treated on donepezil showed good improvement in terms 
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of memory, and motor speed and dexterity. Studies are still on to find definite 
results in this regard. 
Despite all the treatment and care the prognosis remains poor in patients 
with brain metastasis. 90% of patients with brain metastases have impaired 
neurocognitive function at diagnosis. Among them 60% will show further 
declines in Neurocognition within 2-6 months of whole brain 
radiotherapy(95). One of the greatest challenges as a therapist is to distinguish 
treatment effects from progressive disease because the prognosis remains poor 
in many patients 
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CONCLUSION 
At the present neurocognitive decline is an important concern for the 
patients undergoing WBRT for brain metastasis and tumors. But until today no 
treatment has demonstrated better efficacy than WBRT in managing the brain 
metastasis(96). WBRT has given the best response in terms of palliation in 
brain metastasis with significantly good overall survival. Thus it has been 
widely used until today in spite of known side effects. 
. 
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LIMITATION 
• The most important limitation of this study is population size. Brain 
metastasis have poor prognosis and hence few cases will be exposed to 
radiation for palliative purpose. 
•  Duration of the study is also for only 6 months. We allotted participants 
and followed the cases for only 6 months. But there are few rare cases 
on WBRT surviving up to 5 years which were not taken for our study. 
• The absence of control group. But here patients can be considered as his 
own control as we are assessing the neurocognitive change over 6 
months.  
• Lack of advanced neuropsychological battery for assessment of the 
patients. Advanced neuropsychological assessment battery might give 
more specific results. 
• Corticosteroids used on the patients during WBRT might influence 
neurocognitive function. 
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FUTURE DIRECTION 
• Randomized controlled studies on the radiation induced cognitive 
impairment. 
• Better patient selection criteria to identify patients who respond to 
specific procedures. 
• Neurocognitive exercises and Cognitive enhancers to manage patients 
on WBRT. 
• Neuro protective agents 
• Newer research in Stereotactic radio surgery and hippocampal 
avoidance whole brain radiotherapy. 
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Information to Participants 
 
Title: Neurocognition of patients on whole brain radiotherapy: A 
prospective study 
Principal Investigator: Dr. RAJESH M 
 
Name of Participant: 
 
Site:    Department of Radiotherapy, Chennai   
 
You are invited to take part in this research. The information in this document is meant to 
help you decide whether or not to take part. Please feel free to ask if you have any queries or 
concerns. 
 
What is the purpose of research? 
 Whole brain radiotherapy (WBRT) has been used for patients with metastases. The rapidly 
growing tumors in the brain inherently cause cognitive impairment due to pressure on the 
normal tissue and infiltration. Although control of the metastatic brain lesion(s) by WBRT might 
be generally the most important factor for stabilizing neurocognitive functions, paradoxical 
decline in neurocognitive functions (NCFs) can also occur as a sequel of WBRT which cannot 
be negligible. Actually the time course of WBRT-induced NCF decline can vary greatly 
according to the specific neurobehavioral domains measured. Early neurocognitive decline 
occurs within the first one to four months after the patient receives the course of WBRT for 
brain metastases. . So here in our study we are going to assess the cognitive changes occurring 
due to whole brain radiotherapy on the patients through standard neurocognitive assessment 
tools. 
 
The study design 
            Study will be done at Department of Radiotherapy, Madras medical college. 40 
consecutive patients who are physically stable, giving their consent will be taken up for the 
study. Cognitive functions of the patient will be assessed using standardized questionnaire and 
scales. Patients will continue with their radiotherapy treatment for 6 months. Meanwhile 
patients’ cognitive outcome will be measured at 0 months, 3 months and in the end at 6 months. 
 
Study Procedures 
                
            Study will include a population of patients posted for whole brain radiotherapy. They are 
chosen for study if they are physically stable after taking an informed consent. Later, standard 
assessment tools, i.e. MMSE, MoCA, ADLS, HVLT, Binet Kamath intelligence assessment test, 
Trail making test and QOL scale are used to assess the cognition of the patient. Various data 
obtained will be analyzed statistically to get the results. 
. Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical history). By 
signing this document, you will be allowing the research team investigators, other study 
personnel, Institutional Ethics Committee and any person or agency required by law like the 
Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and you will 
not loose any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw 
from this study at any time during the course of the study without giving any reasons. However, 
it is advisable that you talk to the research team prior to discontinuing form the study. 
 
 
Signature of Investigator                                                                      Signature of Participant   
  
                                                                                                             Signature of the Guardian 
 
Date                                                                                                     Date   
(This is only a guideline – Relevant changes to be made as per the study requirements)  
INFORMED CONSENT FORM 
Title of the study:”Neurocognition of  patients on whole brain radiotherapy: A 
prospective study ____________________________________________________”.  
Name of the Participant: ______________________________________________________.  
Name of the Principal (Co-Investigator): _Dr.RAJESH M 
______________________________________.  
Name of the Institution: Institute of mental health 
_____________________________________________________.  
Name and address of the sponsor / agency (ies) (if 
any):__No________________________________ 
_________________________________________________________________________________.  
Documentation of the informed consent   
I _____________________________ have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a participant in  
“Neurocognitive outcome of patients on whole brain radiotherapy: A 
prospective study’ 
1. I have read and understood this consent form and the information provided to me.  
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have been informed the investigator of all the treatments I am taking or have taken in the past 
________ months including any native (alternative) treatment.  
6. I have been advised about the risks associated with my participation in this study.* 
 
7. I have not participated in any research study within the past _________month(s). * 
8. I have not donated blood within the past _______ months—Add if the study involves 
extensive blood sampling. * 
9. I am aware of the fact that I can opt out of the study at any time without having to give any 
reason and this will not affect my future treatment in this hospital. * 
10. I am also aware that the investigator may terminate my participation in the study at any time, 
for any reason, without my consent. * 
11. I hereby give permission to the investigators to release the information obtained from me as 
result of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and 
IEC. I understand that they are publicly presented.  
12. I have understand that  my  identity will be kept confidential if my data are publicly presented  
13. I have had my questions answered to my satisfaction.  
14. I have decided to be in the research study.  
 
 
I am aware that if I have any question during this study, I should contact the investigator. By 
signing this consent form I attest that the information given in this document has been clearly 
explained to me and understood by me, I will be given a copy of this consent document.  
For adult participants:  
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent)  
Name _________________________ Signature_________________ Date________________  
 
Name and Signature of impartial witness (required for illiterate patients):  
 
Name _________________________ Signature_________________ Date________________  
 
Address and contact number of the impartial witness:  
 
 
 
Name and Signature of the investigator or his representative obtaining consent:  
 
Name _________________________ Signature_________________ Date________________  
 
 
 
Name and Signature of the investigator or his representative obtaining consent: 
 
Name _________________________ Signature_________________ Date________________  
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Mini-Mental State Examination (MMSE) 
 
 
 
Patient’s Name:         Date:     
 
Instructions: Ask the questions in the order listed. Score one point for each correct 
response within each question or activity. 
 
Maximum 
Score 
Patient’s 
Score Questions 
5  “What is the year?  Season?  Date?  Day of the week?  Month?” 
5  “Where are we now: State?  County?  Town/city?  Hospital?  Floor?” 
3  
The examiner names three unrelated objects clearly and slowly, then 
asks the patient to name all three of them. The patient’s response is 
used for scoring. The examiner repeats them until patient learns all of 
them, if possible. Number of trials: ___________ 
5  
“I would like you to count backward from 100 by sevens.” (93, 86, 79, 
72, 65, …) Stop after five answers. 
Alternative: “Spell WORLD backwards.” (D-L-R-O-W) 
3  “Earlier I told you the names of three things. Can you tell me what those were?” 
2  Show the patient two simple objects, such as a wristwatch and a pencil, and ask the patient to name them. 
1  “Repeat the phrase: ‘No ifs, ands, or buts.’” 
3  “Take the paper in your right hand, fold it in half, and put it on the floor.” (The examiner gives the patient a piece of blank paper.) 
1  “Please read this and do what it says.” (Written instruction is “Close your eyes.”) 
1  “Make up and write a sentence about anything.” (This sentence must contain a noun and a verb.) 
1  
“Please copy this picture.” (The examiner gives the patient a blank 
piece of paper and asks him/her to draw the symbol below. All 10 
angles must be present and two must intersect.) 
 
 
 
30  TOTAL 
(Adapted from Rovner & Folstein, 1987)
Source: www.medicine.uiowa.edu/igec/tools/cognitive/MMSE.pdf Provided by NHCQF, 0106-410
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Instructions for administration and scoring of the MMSE 
 
Orientation (10 points):  
• Ask for the date. Then specifically ask for parts omitted (e.g., "Can you also tell me what season it 
is?"). One point for each correct answer. 
• Ask in turn, "Can you tell me the name of this hospital (town, county, etc.)?" One point for each 
correct answer. 
 
Registration (3 points): 
• Say the names of three unrelated objects clearly and slowly, allowing approximately one second for 
each. After you have said all three, ask the patient to repeat them. The number of objects the 
patient names correctly upon the first repetition determines the score (0-3). If the patient does not 
repeat all three objects the first time, continue saying the names until the patient is able to repeat all 
three items, up to six trials. Record the number of trials it takes for the patient to learn the words. If 
the patient does not eventually learn all three, recall cannot be meaningfully tested. 
• After completing this task, tell the patient, "Try to remember the words, as I will ask for them in a 
little while." 
 
Attention and Calculation (5 points): 
• Ask the patient to begin with 100 and count backward by sevens. Stop after five subtractions (93, 
86, 79, 72, 65). Score the total number of correct answers. 
• If the patient cannot or will not perform the subtraction task, ask the patient to spell the word "world" 
backwards. The score is the number of letters in correct order (e.g., dlrow=5, dlorw=3). 
 
Recall (3 points): 
• Ask the patient if he or she can recall the three words you previously asked him or her to 
remember. Score the total number of correct answers (0-3). 
 
Language and Praxis (9 points): 
• Naming: Show the patient a wrist watch and ask the patient what it is. Repeat with a pencil. Score 
one point for each correct naming (0-2). 
• Repetition: Ask the patient to repeat the sentence after you ("No ifs, ands, or buts."). Allow only one 
trial. Score 0 or 1. 
• 3-Stage Command: Give the patient a piece of blank paper and say, "Take this paper in your right 
hand, fold it in half, and put it on the floor." Score one point for each part of the command correctly 
executed. 
• Reading: On a blank piece of paper print the sentence, "Close your eyes," in letters large enough 
for the patient to see clearly. Ask the patient to read the sentence and do what it says. Score one 
point only if the patient actually closes his or her eyes. This is not a test of memory, so you may 
prompt the patient to "do what it says" after the patient reads the sentence. 
• Writing: Give the patient a blank piece of paper and ask him or her to write a sentence for you. Do 
not dictate a sentence; it should be written spontaneously. The sentence must contain a subject 
and a verb and make sense. Correct grammar and punctuation are not necessary. 
• Copying: Show the patient the picture of two intersecting pentagons and ask the patient to copy the 
figure exactly as it is. All ten angles must be present and two must intersect to score one point. 
Ignore tremor and rotation. 
 
(Folstein, Folstein & McHugh, 1975)
Source: www.medicine.uiowa.edu/igec/tools/cognitive/MMSE.pdf Provided by NHCQF, 0106-410
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Interpretation of the MMSE 
 
Method Score Interpretation 
Single Cutoff <24 Abnormal 
Range 
<21 
>25 
Increased odds of dementia 
Decreased odds of dementia 
Education 
21 
<23 
<24 
Abnormal for 8th grade education 
Abnormal for high school education 
Abnormal for college education 
Severity 
24-30 
18-23 
0-17 
No cognitive impairment 
Mild cognitive impairment 
Severe cognitive impairment 
 
 
 
Sources:   
• Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the mini-mental state 
examination by age and educational level. JAMA. 1993;269(18):2386-2391. 
• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state 
of patients for the clinician. J Psychiatr Res. 1975;12:189-198. 
• Rovner BW, Folstein MF. Mini-mental state exam in clinical practice. Hosp Pract. 1987;22(1A):99, 103, 106, 
110. 
• Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 
1992;40(9):922-935. 
Source: www.medicine.uiowa.edu/igec/tools/cognitive/MMSE.pdf Provided by NHCQF, 0106-410

THE HOPKINS VERBAL LEARNING TEST 
 
Abstract 
A new test of verbal learning and memory, the Hopkins Verbal Learning Test, 
was developed.  The test consists of three trials of free-recall of a 12-item, 
semantically categorized list, followed by yes/no recognition.  Six parallel forms 
yielded equivalent results in normals. The performance of patients with 
Alzheimer’s disease and chronic amnesia is described.  The test is likely to be 
useful in patients too impaired for more comprehensive memory assessments 
and where repeated testing is necessary. 
 
Clinical practice and research in neuro-psychology often require brief, repeated 
assessments of the same patient over time.  Most of the newer clinical memory 
tests are of limited utility for this purpose because of their length, complexity 
and/or lack of parallel forms.  The WMS-R, for example, require 45 to 60 minutes 
for administration and, at present, is available in only one form.  The California 
Learning Test (Delis, Kramer, Kaplan & Ober, 1986) is gaining popularity as a 
relatively comprehensive verbal memory test, and an alternate form has been 
developed (Delis, et al), but its length and complexity often make it unwieldy for 
use with demented or otherwise difficult-to-test patients.   
 
 
Description of the Test 
Each form of the Hopkins Verbal Learning Test (HVLT) consists of a 12-item 
word list, composed of four words from each of the three semantic categories.  
The subject is instructed to listen carefully as the examiner reads the word list 
and attempt to memorize the words.  The word list is then read to the subject at 
the approximate rate of one word every 2 seconds.  The patient’s free recall of 
the list is recorded.  The same procedure is repeated for two more trials.  After 
the third learning trial, the patient is read 24 words and is asked to say “yes” 
after each word that appeared on the recall list (12 targets) and “no” after each 
word that did not (12 distractors).  Half of the distractors are drawn from the 
same semantic categories as the targets (related distractors) and half are drawn 
from other categories (unrelated distractors). 
 
There are several advantages of the HVLT over many existing memory tests.  
First, it requires no more than 10 minutes to administer.  Second, it is well-
tolerated by even moderately to severely demented patients, while not having a 
ceiling effect (in recall) in neurologically normal subjects.  Third, the existence 
of six comparable forms makes the HVLT particularly useful in research where 
patients are assessed at frequent intervals. 
 
The HVLT was recently employed in a study of the effects of intravenous 
physostigmine in Alzheimer’s disease (Tune et al, in press).  Patients received 
an intravenous infusion of one of three doses of drug, or placebo, on four 
consecutive days.  Memory and other cognitive functions had to be 
administered rapidly, during the 20 minutes of maximum drug effect.  The HVLT 
proved an ideal test for this purpose. 
Hopkins.doc 1 
 
 
 
HOPKINS VERBAL LEARNING TEST 
Form 1:  four-legged animals, precious stones, human dwellings 
 
Part A:  Free Recall 
 
 
 Trial 1 Trial 2  Trial 3 
     
     
EMERALD ________ ________  ________
HORSE ________ ________  ________
TENT ________ ________  ________
SAPPHIRE ________ ________  ________
HOTEL ________ ________  ________
CAVE ________ ________  ________
OPAL ________ ________  ________
TIGER ________ ________  ________
PEARL ________ ________  ________
COW ________ ________  ________
HUT ________ ________  ________
     
# CORRECT 
 
________ ________  ________
HORSE ruby* CAVE balloon coffee LION 
house* OPAL TIGER boat scarf PEARL 
HUT EMERALD SAPPHIRE dog* apartment* penny 
TENT mountain cat* HOTEL COW diamond*
Part B:  Recognition:
  
 
 
 
# True-Positives:______________/12 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
 
 
 
 
Hopkins.doc 2 
 
 
HOPKINS VERBAL LEARNING TEST 
Form 2:  kitchen utensils, alcoholic beverages, weapons 
 
Part A:  Free Recall 
 Trial 1 Trial 2  Trial 3 
     
     
FORK ________ ________  ________
RUM ________ ________  ________
PAN ________ ________  ________
PISTOL ________ ________  ________
SWORD ________ ________  ________
SPATULA ________ ________  ________
BOURBON ________ ________  ________
VODKA ________ ________  ________
POT ________ ________  ________
COW ________ ________  ________
HUT ________ ________  ________
WINE ________ ________  ________
# CORRECT ________ ________  ________
     
     
 
Part B:  Recognition: 
 
 
spoon* PISTOL doll whiskey* FORK POT 
harmonica can opener* SWORD pencil gun* VODKA 
knife* RUM trout BOMB PAN gold 
WINE lemon SPATULA BOURBON beer* RIFLE 
 
 
# True-Positives:______________/12 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
 
 
 
 
Hopkins.doc 3 
HOPKINS VERBAL LEARNING TEST 
Form 3: musical instruments, fuels, food flavorings 
 
Part A:  Free Recall
 
 
Trial 1 Trial 2  Trial 3 
     
     
SUGAR ________ ________  ________
TRUMPET ________ ________  ________
VIOLIN ________ ________  ________
COAL ________ ________  ________
GARLIC ________ ________  ________
KEROSINE ________ ________  ________
VANILLA ________ ________  ________
WOOD ________ ________  ________
CLARINET ________ ________  ________
FLUTE ________ ________  ________
CINNAMON ________ ________  ________
GASOLINE ________ ________  ________
# CORRECT ________ ________  ________
     
     
Part B:  Recognition: 
 
 
 
 
 
pepper* GARLIC WOOD drum* oil* SUGAR 
Harmonica salt* priest chair COAL CLARINET
TRUMPET basement CINNAMON FLUTE electricity* Moon 
KEROSINE VANILLA GASOLINE sand piano* VIOLIN 
# True-Positives:______________/12 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
 
 
 
 
 
Hopkins.doc 4 
HOPKINS VERBAL LEARNING TEST 
Form 4: birds, articles of clothing, carpenter’s tools 
 
Part A:  Free Recall 
 
 
Trial 1 Trial 2  Trial 3 
     
     
CANARY ________ ________  ________
SHOES ________ ________  ________
EAGLE ________ ________  ________
BLOUSE ________ ________  ________
NAILS ________ ________  ________
CROW ________ ________  ________
BLUEBIRD ________ ________  ________
SCREWDRIVER ________ ________  ________
PANTS ________ ________  ________
CHISEL ________ ________  ________
SKIRT ________ ________  ________
WRENCH ________ ________  ________
# CORRECT ________ ________  ________
     
     
Part B:  Recognition: 
 
 
 
 
 
BLUEBIRD shirt* CHISEL EAGLE chocolate robin* 
chapel SCREWDRIVER CROW sparrow* WRENCH PANTS 
NAILS socks* child SHOES hair hammer*
CANARY apple SKIRT saw* silver BLOUSE 
# True-Positives:______________/12 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
 
 
 
 
 
Hopkins.doc 5 
HOPKINS VERBAL LEARNING TEST 
Form 5:  occupations/professions, sports, vegetables 
 
Part A:  Free Recall 
 Trial 1 Trial 2  Trial 3 
     
     
TEACHER ________ ________  ________
BASKETBALL ________ ________  ________
LETTUCE ________ ________  ________
DENTIST ________ ________  ________
TENNIS ________ ________  ________
BEAN ________ ________  ________
ENGINEER ________ ________  ________
POTATO ________ ________  ________
PROFESSOR ________ ________  ________
GOLF ________ ________  ________
CORN ________ ________  ________
SOCCER ________ ________  ________
# CORRECT ________ ________  ________
     
     
Part B:  Recognition: 
 
 
 
 
 
# True-Positives:______________/12 
TENNIS football* PROFESSOR spinach* lawyer* submarine
GOLF DENTIST LETTUCE spider water BEAN 
BASKETBALL doctor* CORN baseball* TEACHER snake 
carrot* ENGINEER glove SOCCER POTATO tulip 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
 
 
 
 
 
 
Hopkins.doc 6 
HOPKINS VERBAL LEARNING TEST 
Form 6:  fish, parts of a building, phenomens 
 
Part A:  Free Recall 
 Trial 1 Trial 2  Trial 3 
     
     
SHARK ________ ________  ________
WALL ________ ________  ________
HERRING ________ ________  ________
RAIN ________ ________  ________
FLOOR ________ ________  ________
HAIL ________ ________  ________
CATFISH ________ ________  ________
ROOF ________ ________  ________
SALMON ________ ________  ________
STORM ________ ________  ________
CEILING ________ ________  ________
SNOW ________ ________  ________
# CORRECT ________ ________  ________
     
     
Part B:  Recognition: 
 
 
 
 
 
# True-Positives:______________/12 
HAIL bass* SNOW bank FLOOR mustard 
window* CEILING canyon RAIN ladder STORM 
HERRING SALMON tornado* trout* melon ROOF 
SHARK hurricane* elbow CATFISH WALL door* 
 
# False-Positive Errors: Related:____________/6 Unrelated:___________/6 
 
Discrimination Index:       (# True-Positives) – (# False-Positives)  =  ________________ 
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Patient Name:______________________            Date:_____________ 
Patient ID #________________________ 
 
Katz Index of Independence in Activities of Daily Living 
 
Activities  
Points (1 or 0) 
Independence  
(1 Point)  
 
NO supervision, direction or personal 
assistance. 
Dependence  
(0 Points)  
 
WITH supervision, direction, 
personal assistance or total care. 
 
BATHING  
 
Points: __________ 
(1 POINT)  Bathes self completely or 
needs help in bathing only a single part 
of the body such as the back, genital 
area or disabled extremity. 
 
(0 POINTS) Need help with 
bathing more than one part of the 
body, getting in or out of the tub or 
shower. Requires total bathing 
DRESSING  
 
Points: __________ 
(1 POINT)  Get clothes from closets 
and drawers and puts on clothes and 
outer garments complete with fasteners. 
May have help tying shoes. 
 
(0 POINTS)  Needs help with 
dressing self or needs to be 
completely dressed. 
TOILETING  
 
Points: __________ 
(1 POINT)  Goes to toilet, gets on and 
off, arranges clothes, cleans genital area 
without help. 
 
(0 POINTS) Needs help 
transferring to the toilet, cleaning 
self or uses bedpan or commode.  
TRANSFERRING  
 
Points: __________  
(1 POINT)  Moves in and out of bed or 
chair unassisted. Mechanical transfer 
aids are acceptable 
 
(0 POINTS) Needs help in moving 
from bed to chair or requires a 
complete transfer.  
CONTINENCE  
 
Points: __________ 
(1 POINT)  Exercises complete self 
control over urination and defecation. 
(0 POINTS)  Is partially or totally 
incontinent of bowel or bladder 
FEEDING  
 
Points: __________ 
(1 POINT)  Gets food from plate into 
mouth without help. Preparation of food 
may be done by another person. 
 
(0 POINTS)  Needs partial or total 
help with feeding or requires 
parenteral feeding. 
 
TOTAL POINTS: ________           SCORING:  6 = High (patient independent)   0 = Low (patient very dependent 
 
 
 
 
Source:   
try this: Best Practices in Nursing Care to Older Adults, The Hartford Institute for Geriatric Nursing, New York University, College of 
Nursing, www.hartfordign.org. 
 
 
 
 
 
Patient Name:______________________            Date:_____________ 
Patient ID #________________________ 
LAWTON - BRODY 
INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (I.A.D.L.) 
 
Scoring: For each category, circle the item description that most closely resembles the client’s highest functional 
level (either 0 or 1). 
 
A. Ability to Use Telephone  E. Laundry  
1. Operates telephone on own initiative-looks 
up and dials numbers, etc. 
2. Dials a few well-known numbers 
3. Answers telephone but does not dial 
4. Does not use telephone at all 
1 
 
1 
1 
0 
1. Does personal laundry completely 
2. Launders small items-rinses stockings, etc. 
3. All laundry must be done by others 
 
1 
1 
0 
B. Shopping   F. Mode of Transportation  
1. Takes care of all shopping needs 
     independently 
2. Shops independently for small purchases 
3. Needs to be accompanied on any shopping 
    trip 
4. Completely unable to shop 
 
1 
 
0 
0 
 
0 
1. Travels independently on public transportation or 
drives own car 
2. Arranges own travel via taxi, but does not    
otherwise use public transportation 
3. Travels on public transportation when   
accompanied by another 
4. Travel limited to taxi or automobile with 
assistance of another 
5. Does not travel at all 
1 
 
1 
 
1 
 
0 
 
0 
C. Food Preparation   G. Responsibility for Own Medications  
1. Plans, prepares and serves adequate meals 
     independently 
2. Prepares adequate meals if supplied with 
    ingredients 
3. Heats, serves and prepares meals, or 
    prepares meals, or prepares meals but does 
    not maintain adequate diet 
4. Needs to have meals prepared and served 
1 
 
0 
 
0 
 
 
0 
1. Is responsible for taking medication in correct 
dosages at correct time 
2. Takes responsibility if medication is prepared in 
advance in separate dosage 
3. Is not capable of dispensing own medication 
 
1 
 
0 
 
0 
 
D. Housekeeping   H. Ability to Handle Finances  
1. Maintains house alone or with occasional 
    assistance (e.g. "heavy work domestic help") 
2. Performs light daily tasks such as dish 
    washing, bed making 
3. Performs light daily tasks but cannot 
   maintain acceptable level of cleanliness 
4. Needs help with all home maintenance 
     tasks 
5. Does not participate in any housekeeping 
    tasks 
1 
 
1 
 
1 
 
1 
 
0 
 
1. Manages financial matters independently 
(budgets, writes checks, pays rent, bills, goes to 
bank), collects and keeps track of income 
2. Manages day-to-day purchases, but needs help      
with banking, major purchases, etc. 
3. Incapable of handling money 
 
1 
 
 
1 
 
0 
Score
 
Score
 
Total score__________________
A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women 
and 0 through 5 for men to avoid potential gender bias. 
 
 
Source:  try this: Best Practices in Nursing Care to Older Adults, The Hartford Institute for Geriatric Nursing,  
New York University, College of Nursing, www.hartfordign.org. 
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WHOQOL-BREF 
 
The following questions ask how you feel about your quality of life, health, or other areas of 
your life. I will read out each question to you, along with the response options. Please choose 
the answer that appears most appropriate. If you are unsure about which response to give 
to a question, the first response you think of is often the best one. 
 
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think 
about your life in the last four weeks. 
 
  Very poor Poor Neither poor nor good  Good Very good 
1. How would you rate your 
quality of life? 1 2 3 4 5 
 
 
  Very 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Very satisfied 
2. How satisfied are you with your 
health? 1 2 3 4 5 
 
The following questions ask about how much you have experienced certain things in the last 
four weeks. 
  Not at all A little A moderate amount Very much 
An extreme 
amount 
3. To what extent do you feel that 
physical pain prevents you 
from 
doing what you need to do? 
5 4 3 2 1 
4. How much do you need any 
medical treatment to function 
in your daily life? 
5 4 3 2 1 
5. How much do you enjoy life? 1 2 3 4 5 
6. To what extent do you feel your 
life to be meaningful? 1 2 3 4 5 
 
  Not at all A little A moderate amount Very much Extremely 
7. How well are you able to 
concentrate? 1 2 3 4 5 
8. How safe do you feel in your 
daily life? 1 2 3 4 5 
9. How healthy is your physical 
environment? 1 2 3 4 5 
 
The following questions ask about how completely you experience or were able to do certain 
things in the last four weeks. 
  Not at all A little Moderately Mostly Completely 
10. Do you have enough energy for 
everyday life? 1 2 3 4 5 
11. Are you able to accept your 
bodily appearance? 1 2 3 4 5 
12. Have you enough money to 
meet your needs? 1 2 3 4 5 
13. How available to you is the 
information that you need in 
your day-to-day life? 
1 2 3 4 5 
14. To what extent do you have the 
opportunity for leisure 
activities? 
1 2 3 4 5 
 
 
  Very poor Poor Neither poor nor good  Good Very good 
15. How well are you able to get 
around? 1 2 3 4 5 
 
 
  Very 
dissatisfied Dissatisfied 
Neither 
satisfied nor 
dissatisfied 
Satisfied Very satisfied 
16. How satisfied are you with your 
sleep? 1 2 3 4 5 
17. How satisfied are you with 
your ability to perform your 
daily living activities? 
1 2 3 4 5 
18. How satisfied are you with 
your capacity for work? 1 2 3 4 5 
19. How satisfied are you with 
yourself? 1 2 3 4 5 
 
20. How satisfied are you with your 
personal relationships? 1 2 3 4 5 
21. How satisfied are you with 
your sex life? 1 2 3 4 5 
22. How satisfied are you with the 
support you get from your 
friends? 
1 2 3 4 5 
23. How satisfied are you with the 
conditions of your living place? 1 2 3 4 5 
24. How satisfied are you with your 
access to health services? 1 2 3 4 5 
25. How satisfied are you with 
your transport? 1 2 3 4 5 
 
The following question refers to how often you have felt or experienced certain things in the 
last four weeks. 
  Never Seldom Quite often Very often Always 
26. How often do you have 
negative feelings such as blue 
mood, despair, anxiety, 
depression? 
5 4 3 2 1 
 
Do you have any comments about the assessment? 
 
 
 
 
 
[The following table should be completed after the interview is finished] 
 
Transformed scores*  Equations for computing domain scores Raw score 
4-20 0-100 
27. Domain 1 (6-Q3) + (6-Q4) + Q10 + Q15 + Q16 + Q17 + Q18 
      +      +     +    +    +    +   a. = b: c: 
28. Domain 2 Q5 + Q6 + Q7 + Q11 + Q19 + (6-Q26) 
  +  +  +     +     +    a. = b: c: 
29. Domain 3 Q20 + Q21 + Q22 
   +    +   a. = b: c: 
30. Domain 4 Q8 + Q9 + Q12 + Q13 + Q14 + Q23 + Q24 + Q25 
  +  +   +    +    +    +    +   a. = b: c: 
 
* See Procedures Manual, pages 13-15 
 
Trail Making (Part A)
Patient’s Name:                                                                     Date:                                               
Trail Making (Part A) – SAMPLE
Trail Making (Part B)
Patient’s Name:                                                                     Date:                                               
Trail Making (Part B) – SAMPLE
Instructions:
Step 1: Give the patient a copy of the Trail Making Test (Part A) worksheet and a pen or pencil.
Step 2: Demonstrate the test to the patient using the sample sheet (Trail Making (Part A) –
SAMPLE).
Step 3: Time the patient, as he or she follows the “trail” made by the numbers on the test.
Step 4: Record the time.
Step 5: Repeat for Trail Making Test (Part B).
Scoring:
Average Deficient Rule of Thumb
Trail A 29 seconds > 78 seconds Most in 90 seconds
Trail B 75 seconds > 273 Most in 3 minutes
Source:
• Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Percept
Motor Skills 1958; 8: 271-276.
• Lezak MD (1995) Neuropsychological assessment, 3rd edn. New York: Oxford University Press.
• Corrigan JD, Hinkeldey MS. Relationships between Parts A and B of the Trail Making Test. J Clin
Psychol 1987;43:402–9.
Comparison of recognition scores and discrimination scores over 0, 3 and 6 months 
of HVLT:  
 
Form 1 recognition scores 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 .325 .252 .612 -.304 .954 
3 -3.475* .291 .000 -4.203 -2.747 
2 1 -.325 .252 .612 -.954 .304 
3 -3.800* .153 .000 -4.182 -3.418 
3 1 3.475* .291 .000 2.747 4.203 
2 3.800* .153 .000 3.418 4.182 
 
Form 1 discrimination index 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 .075 .184 1.000 -.385 .535 
3 3.075* .210 .000 2.550 3.600 
2 1 -.075 .184 1.000 -.535 .385 
3 3.000* .203 .000 2.493 3.507 
3 1 -3.075* .210 .000 -3.600 -2.550 
2 -3.000* .203 .000 -3.507 -2.493 
 
Form 2 recognition scores 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 -.150 .166 1.000 -.566 .266 
3 .350 .234 .426 -.234 .934 
2 1 .150 .166 1.000 -.266 .566 
3 .500* .179 .024 .052 .948 
3 1 -.350 .234 .426 -.934 .234 
2 -.500* .179 .024 -.948 -.052 
 
 
 
Form 2  discrimination index 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 -.500 .226 .100 -1.067 .067 
3 .425 .226 .203 -.141 .991 
2 1 .500 .226 .100 -.067 1.067 
3 .925* .194 .000 .439 1.411 
3 1 -.425 .226 .203 -.991 .141 
2 -.925* .194 .000 -1.411 -.439 
 
Form 3 recognition scores 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 -.200 .209 1.000 -.724 .324 
3 .525 .280 .204 -.175 1.225 
2 1 .200 .209 1.000 -.324 .724 
3 .725* .273 .034 .043 1.407 
3 1 -.525 .280 .204 -1.225 .175 
2 -.725* .273 .034 -1.407 -.043 
 
Form 3 discrimination index 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 -.150 .204 1.000 -.661 .361 
3 .400 .189 .122 -.072 .872 
2 1 .150 .204 1.000 -.361 .661 
3 .550* .196 .023 .060 1.040 
3 1 -.400 .189 .122 -.872 .072 
2 -.550* .196 .023 -1.040 -.060 
 
Form 4 recognition scores 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 -.325 .219 .437 -.873 .223 
3 .250 .189 .578 -.222 .722 
2 1 .325 .219 .437 -.223 .873 
3 .575* .192 .015 .094 1.056 
3 1 -.250 .189 .578 -.722 .222 
2 -.575* .192 .015 -1.056 -.094 
Form 4 discrimination index 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.a 
95% Confidence 
Interval for 
Differencea 
Lower 
Bound 
Upper 
Bound 
1 2 -.025 .181 1.000 -.477 .427 
3 .400 .240 .309 -.200 1.000 
2 1 .025 .181 1.000 -.427 .477 
3 .425 .214 .164 -.112 .962 
3 1 -.400 .240 .309 -1.000 .200 
2 -.425 .214 .164 -.962 .112 
 
 
Form 5 recognition scores 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.a 
95% Confidence 
Interval for 
Differencea 
Lower 
Bound 
Upper 
Bound 
1 2 -.350 .303 .765 -1.108 .408 
3 0.000 .209 1.000 -.522 .522 
2 1 .350 .303 .765 -.408 1.108 
3 .350 .204 .284 -.161 .861 
3 1 0.000 .209 1.000 -.522 .522 
2 -.350 .204 .284 -.861 .161 
 
Form 5 discrimination index 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
1 2 .150 .210 1.000 -.377 .677 
3 .525* .206 .044 .011 1.039 
2 1 -.150 .210 1.000 -.677 .377 
3 .375 .192 .173 -.105 .855 
3 1 -.525* .206 .044 -1.039 -.011 
2 -.375 .192 .173 -.855 .105 
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51 m 10th electrician 15000 m scc carcinoma lung 85 26 3 3 19 17 8 18 29 5 3 6 3 2 4 6 4 5 6 9 8 5 5 6 10 8 4 4 5 9 8 4 5 6 9 8 4 4 5 9 9 3 4 6 10 9 36 88 29 4 3 17 16 7 18 28 5 3
40 m diploma business 10000 UM scc carcinoma lung 94 30 6 6 23 16 7 21 30 5 3 6 3 2 5 6 4 5 6 10 1 5 5 6 9 9 4 6 6 10 10 5 6 7 9 8 3 4 6 11 10 4 5 7 11 9 45 160 29 6 6 21 14 7 19 29 5 3
50 m 9th coolie 1000 m scc carcinoma lung 74 19 4 4 18 13 8 22 19 3 3 5 3 1 2 3 3 3 4 8 7 2 3 5 9 7 3 3 4 9 7 3 3 3 8 7 3 4 4 9 7 2 3 4 8 6 45 160 19 4 4 18 17 7 21 17 3 3
58 m 8th business 2000 m adenocarcinoma 86 27 6 4 24 21 11 25 27 4 3 6 3 1 4 6 4 6 8 9 7 7 7 8 10 8 6 6 7 10 7 8 8 9 10 7 5 5 7 8 6 6 6 7 10 7 53 105 25 4 2 18 16 7 20 23 4 3
60 m plus 2 business 4000 m scc carcinoma lung 70 12 2 3 19 13 8 21 12 2 3 4 1 0 0 2 3 3 4 10 8 2 2 3 9 6 2 3 4 9 7 3 4 5 9 7 2 3 3 9 6 3 3 4 10 7 85 175 19 3 2 14 16 8 21 21 4 3
48 m 5th farmer 4000 m scc carcinoma lung 70 25 6 5 23 18 8 20 18 4 3 3 1 1 3 3 4 4 7 10 7 5 6 8 10 8 5 5 7 11 8 4 5 6 9 7 4 4 5 9 8 5 5 7 10 8 68 157 16 2 2 19 15 7 21 9 1 3
58 m 7th coolie 1000 m scc carcinoma lung 72 21 5 4 20 18 10 20 19 3 3 4 1 1 3 4 5 6 5 10 8 4 5 6 11 8 3 5 5 9 7 3 4 5 10 6 3 5 6 10 9 3 4 6 9 8 56 98 22 4 3 17 17 7 19 17 3 3
60 m diploma business 5000 m adenocarcinoma 87 26 5 4 22 15 7 21 29 5 3 6 3 2 4 6 5 5 6 11 9 4 5 7 12 10 4 5 7 10 8 5 5 6 11 10 4 6 7 10 8 3 5 6 10 9 42 100 26 4 3 18 14 5 18 29 5 3
45 m 5th coolie 4000 m melanocytoma GI 81 19 2 2 23 20 8 21 16 2 3 3 1 1 2 4 4 5 7 11 10 5 5 6 10 9 5 5 7 11 9 5 6 8 12 11 4 5 6 10 8 4 5 7 10 8 60 111 22 2 2 16 13 7 20 18 2 3
66 m 6th coolie 2000 m small cell ca lung 70 14 1 2 16 11 10 18 12 4 3 0 1 1 1 2 3 3 3 9 6 3 4 4 9 6 2 3 4 10 6 1 2 3 9 5 2 3 4 9 7 3 4 4 8 6 92 225 13 3 3 13 11 7 17 19 4 3
66 m 2nd coolie 1000 m Small carcinoma lung 80 19 5 2 23 16 7 21 25 4 3 6 2 2 3 5 4 5 6 10 8 3 5 6 11 9 4 5 7 11 10 5 5 7 11 10 4 5 7 10 8 4 5 6 9 8 48 110 22 5 2 21 14 7 19 23 3 3
58 m BSc teacher 10000 m small cell ca lung 90 30 6 6 22 16 10 24 21 2 2 6 1 1 4 5 4 5 6 9 7 4 6 6 10 8 3 4 6 10 7 3 4 6 10 8 3 5 6 11 8 4 5 6 10 9 33 63 27 5 4 18 14 7 19 17 2 2
66 m 6th coolie 1000 m small cell ca lung 70 12 2 1 17 17 10 21 13 2 2 3 0 1 2 3 2 2 3 8 5 2 3 3 9 6 2 3 4 10 7 2 2 3 8 7 2 3 4 1 7 2 2 5 10 8 94 190 10 2 1 15 14 7 17 10 1 2
60 m 10th business 6000 m small cell ca lung 73 26 6 6 24 21 11 25 18 3 3 4 1 1 3 3 3 4 5 9 7 3 5 6 10 7 3 4 5 10 8 4 4 6 11 7 3 5 5 10 7 4 5 6 10 7 60 145 20 2 3 17 17 7 19 15 3 3
29 m plus 2 coolie 6000 m renal cell carcinoma 75 30 6 5 19 15 8 23 29 5 3 6 3 2 4 6 5 6 8 10 9 4 6 9 11 10 5 6 8 11 9 4 5 6 12 10 3 5 7 10 10 5 6 8 10 9 46 84 30 6 3 17 13 6 20 29 5 3
58 m 8th coolie 10000 m small cell ca lung 88 15 6 5 21 18 10 25 18 3 3 4 1 1 3 3 4 4 6 10 8 3 4 5 9 7 3 4 4 11 6 3 4 6 10 8 2 4 5 9 7 3 4 6 10 7 107 171 15 2 2 16 10 6 20 15 3 3
62 m 3rd coolie 0 m small cell ca lung 70 13 3 2 18 14 9 22 14 3 3 1 1 1 2 3 3 3 3 9 6 3 3 4 9 7 3 5 5 10 7 3 4 5 9 6 3 3 4 9 6 3 3 4 9 6 123 204 16 3 2 17 14 6 17 18 3 3
70 m 4th farmer 1000 m small cell ca lung 80 27 6 5 19 18 8 25 28 5 3 6 2 2 4 6 4 5 6 10 9 3 5 6 11 9 4 5 7 10 9 3 4 6 11 9 4 6 7 11 9 5 5 6 10 8 40 94 27 4 2 18 16 6 20 28 5 3
58 m bsc coolie 1500 m oesophageal ca 96 15 4 3 15 15 6 13 12 2 2 3 0 1 0 4 3 4 4 9 5 2 3 4 9 6 2 4 4 8 6 2 3 3 9 7 2 3 4 9 6 2 4 4 10 7 78 168 19 3 2 13 11 7 17 17 2 3
58 f plus 2 homemaker 0 m small cell ca lung 80 22 4 3 21 17 8 24 26 4 3 5 3 2 3 6 3 5 5 10 8 3 4 5 9 7 3 4 6 11 8 3 4 5 10 8 3 4 5 10 8 4 4 6 10 10 70 106 19 2 2 18 17 6 14 22 0 3
48 f 5th homemaker 0 m breast cancer 76 17 6 4 13 17 9 22 11 0 3 4 1 0 1 2 2 2 4 8 5 2 3 3 9 6 2 2 3 7 5 2 3 4 8 5 2 3 3 9 5 3 3 3 8 4 76 246 17 4 3 15 14 8 21 12 1 3
55 f 10th business 1000 m breast cancer 80 19 4 3 15 15 6 13 23 3 3 6 3 0 2 6 4 5 5 7 4 5 5 9 7 3 4 5 9 7 7 4 5 6 9 6 3 4 5 10 8 3 3 4 10 8 76 173 22 3 2 14 11 6 12 19 3 3
68 f 3rd coolie 200 m breast cancer 75 10 2 1 18 12 6 18 14 2 2 3 1 1 3 2 2 3 3 8 5 2 3 4 9 7 2 3 4 9 7 2 3 5 10 7 3 3 4 10 6 3 3 3 10 8 68 176 13 2 2 18 12 5 16 13 2 3
70 f 6th coolie 500 m breast cancer 81 22 4 5 19 15 5 19 20 4 3 5 1 0 3 4 4 5 5 9 7 3 4 5 10 7 4 5 5 7 6 5 5 6 9 7 4 5 6 10 7 3 3 5 9 7 56 124 20 4 3 18 16 5 16 19 4 3
61 f  10th coolie 2000 m small cell ca lung 85 27 6 5 19 18 8 25 26 2 3 6 3 2 4 6 4 5 6 11 7 4 5 7 9 6 3 4 6 10 8 4 5 6 9 7 3 5 6 10 8 3 3 5 8 7 56 121 24 4 3 18 16 6 20 24 2 3
37 f 9th farmer 1000 m breast cancer 78 7 1 0 11 16 9 21 3 0 0 2 1 0 0 0 1 2 3 7 4 1 2 2 8 4 2 2 2 9 4 1 2 2 8 5 1 2 2 7 3 1 2 2 8 4 114 350 12 2 2 12 14 7 19 11 1 2
54 f 4th homemaker 0 m small cell ca lung 76 22 5 4 20 15 11 24 24 4 3 5 1 1 3 5 4 4 5 9 7 4 6 6 9 7 4 5 6 10 6 5 5 6 11 8 4 4 6 10 8 4 5 5 10 7 67 126 23 3 3 16 12 7 17 21 3 3
62 f 10th homemaker 0 m small cell ca lung 85 13 5 3 18 15 4 18 10 0 2 3 1 0 2 2 3 3 4 10 7 3 4 5 11 7 2 3 4 11 8 3 4 5 9 6 3 3 4 8 6 2 2 4 9 7 121 250 16 5 3 16 13 6 16 16 1 3
56 f 2nd farmer 500 m breast cancer 81 23 6 4 19 16 7 24 16 2 1 5 1 0 3 4 3 4 5 10 9 3 4 6 9 7 4 4 5 10 8 3 3 4 10 8 3 3 5 9 8 3 4 5 10 7 86 191 23 3 3 18 14 7 16 18 2 1
66 f nil homemaker 0 m breast cancer 78 8 2 1 17 16 7 21 6 0 2 1 1 0 0 2 2 2 3 7 4 2 1 2 7 4 2 2 2 8 4 1 2 2 6 4 2 2 3 8 6 2 2 3 7 4 141 >350 12 2 3 16 14 5 14 13 2 2
65 f plus 2 business 2000 m breast cancer 84 27 6 4 19 15 5 19 26 2 3 6 3 2 4 6 4 4 5 11 9 3 4 6 10 8 4 5 7 10 8 4 5 6 11 9 4 4 5 10 10 5 5 6 10 9 67 114 21 2 2 18 16 5 16 24 2 3
56 f 6th homemaker 500 m breast cancer 75 15 4 3 20 15 10 25 15 1 3 4 1 1 2 3 3 3 4 9 7 4 4 5 10 7 3 4 5 11 8 3 4 5 10 7 4 5 6 9 8 3 4 5 10 8 76 198 19 4 4 17 15 6 20 20 2 3
60 f 9th farmer 500 m small cell ca lung 78 11 2 2 16 15 8 20 7 0 2 1 0 0 2 2 2 2 3 8 5 2 2 2 9 6 2 3 3 7 4 2 3 4 8 6 3 3 4 9 6 2 3 3 8 4 87 223 15 2 2 20 10 5 13 13 1 2
54 f BA business 2000 m small cell ca lung 92 30 6 6 20 16 11 25 28 5 3 6 2 2 4 6 5 6 8 11 10 4 5 7 10 9 5 6 7 10 8 5 6 7 9 7 5 6 7 11 8 4 6 7 9 8 33 66 28 4 5 17 17 10 19 26 5 3
62 f 10th business 500 m small cell ca lung 82 24 6 5 18 15 10 22 17 4 1 3 0 1 3 5 3 4 5 11 8 3 3 5 9 7 3 4 5 9 8 2 4 5 9 8 3 4 5 10 6 3 4 5 9 8 52 125 25 6 5 18 13 7 19 20 4 2
67 f 9th homemaker 0 m breast cancer 80 14 4 3 18 16 8 22 19 2 3 4 2 1 3 4 4 5 6 12 8 3 3 4 9 7 4 4 5 8 7 4 4 6 8 6 3 3 4 8 6 2 3 4 11 7 66 132 15 4 2 16 13 6 20 19 2 3
56 f 5th homemaker 500 m breast cancer 88 26 6 4 20 19 9 23 23 3 3 6 3 0 2 6 4 6 6 10 8 4 5 5 9 7 5 6 7 9 8 5 6 7 11 8 4 5 6 9 8 4 5 6 10 8 91 138 23 5 3 18 17 7 17 19 3 3
58 f 10th farmer 500 m small cell ca lung 83 17 4 3 21 18 9 24 15 4 3 1 0 1 2 4 3 3 4 8 7 3 4 5 9 8 3 4 4 10 7 3 4 6 10 7 4 5 6 11 7 2 3 5 9 7 59 104 20 4 3 20 18 7 19 19 4 3
66 f 5th homemaker 500 m adenocarcinoma 85 13 4 3 18 14 9 22 15 3 3 1 1 1 3 3 2 3 4 9 7 3 4 5 10 7 2 3 4 9 8 3 4 6 10 8 3 4 5 9 7 3 5 5 10 9 80 125 16 4 3 17 14 6 17 18 3 3
54 m 9th carpenter 500 m breast cancer 77 23 6 5 20 15 7 21 20 4 3 5 1 0 3 4 3 4 6 11 9 3 4 5 11 9 4 5 6 10 7 4 4 5 8 6 5 5 6 10 8 4 5 5 11 7 76 165 20 4 3 18 14 6 20 20 4 3
68 m 5th farmer 1000 m small cell ca lung expired
62 m 9th coolie 1000 m small cell ca lung expired
60 f 5th homemaker 500 m breast cancer expired
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1
6 3 2 3 6 5 5 6 9 7 4 5 6 10 8 3 5 6 9 7 5 6 7 11 9 4 4 6 10 9 5 6 6 12 11 44 92 29 3 2 13 14 5 16 25 5 3 5 2 1 3 6 4 5 7 10 9 3 5 6 11 7 4 4 6 9 8 4
6 3 2 4 6 3 4 5 9 7 4 4 5 10 9 3 4 5 11 9 3 4 6 10 9 4 6 7 9 8 4 5 6 10 8 45 168 28 6 5 14 13 5 15 28 5 3 6 3 2 3 6 3 4 4 9 7 5 6 7 10 9 4 5 5 9 8 4
5 1 1 1 4 2 3 3 8 6 2 3 4 9 6 2 3 3 8 6 2 3 4 10 6 3 4 4 8 6 3 3 4 10 7 40 168 16 2 2 17 13 6 17 15 3 3 2 1 1 1 4 2 3 3 9 7 2 3 4 8 6 2 3 5 9 6 3
6 1 1 3 5 4 5 5 10 7 3 4 5 10 8 4 5 5 9 7 5 5 7 11 8 4 5 5 10 8 5 4 7 10 9 67 124 20 2 1 14 12 4 13 17 3 3 4 1 1 2 3 2 3 4 8 6 3 3 4 9 6 3 3 5 9 6 3
5 1 1 3 4 4 6 6 10 6 5 5 6 11 9 4 5 6 9 7 4 5 5 9 6 5 5 6 9 6 4 4 5 9 7 90 163 9 1 1 12 14 5 15 13 2 3 4 1 0 1 2 2 3 3 9 7 3 4 4 8 6 3 3 4 10 7 2
1 0 0 2 2 3 4 5 9 7 4 3 6 9 7 4 5 6 10 8 3 4 6 9 6 3 5 6 11 8 4 5 5 11 8 71 178 15 2 2 13 12 6 17 13 1 3 3 1 1 2 2 3 4 5 9 6 3 4 4 10 7 3 4 5 11 7 2
4 1 1 2 3 2 4 5 8 6 2 4 5 9 7 3 4 5 9 7 2 4 5 8 7 2 4 5 9 6 2 4 5 8 6 60 97 19 2 2 15 13 5 17 17 3 3 4 1 1 2 3 2 3 5 9 8 3 4 4 7 5 2 4 4 9 8 2
6 3 2 4 6 3 4 5 9 8 3 5 5 10 9 3 4 6 10 9 4 4 6 11 10 4 5 6 11 10 5 5 7 10 7 51 110 29 5 3 15 10 4 13 27 5 3 5 3 2 3 6 3 4 5 9 7 3 4 6 10 8 4 5 7 10 9 4
3 1 1 3 5 5 5 6 9 7 5 6 7 10 8 6 6 7 10 8 6 6 9 10 8 5 5 7 9 7 4 5 6 10 8 57 108 19 2 1 13 11 6 14 13 1 3 1 1 1 2 4 3 4 5 8 6 4 4 6 10 8 4 5 6 11 8 4
5 1 1 2 3 4 4 6 9 7 4 5 7 10 7 5 5 6 11 7 4 5 5 11 7 4 6 6 9 8 5 6 7 10 9 84 206 13 1 1 15 11 8 20 17 4 3 3 1 1 2 3 3 4 5 10 7 4 5 6 11 8 4 4 5 10 7 4
5 2 2 3 5 3 4 5 10 7 3 4 6 11 8 4 5 7 10 7 3 5 6 10 8 3 5 6 11 8 4 4 5 11 8 56 125 18 3 2 14 13 5 15 19 3 3 4 2 1 2 4 3 3 4 9 7 3 4 5 11 7 2 4 5 11 9 3
4 1 1 2 5 3 4 5 9 8 4 5 6 10 9 2 4 5 9 7 3 4 5 10 8 3 4 5 10 7 3 5 6 10 7 37 76 25 4 2 15 15 5 16 15 2 2 3 0 1 2 5 3 4 4 9 6 3 4 4 11 8 3 5 6 10 7 3
2 0 1 1 3 2 2 3 8 5 2 2 3 9 7 2 3 4 9 6 2 2 3 10 7 2 2 3 10 6 2 3 4 9 6 98 201 9 2 1 15 13 5 10 7 1 2 1 0 0 1 2 2 2 3 8 5 2 2 2 8 6 2 3 2 9 6 2
2 1 1 3 2 3 3 4 9 7 2 3 5 10 8 3 3 4 9 7 3 4 5 10 8 2 3 4 9 7 3 4 6 10 8 71 157 18 3 2 15 13 5 17 13 2 2 1 0 1 1 2 2 2 3 9 6 2 2 3 8 7 2 2 3 8 5 3
6 3 2 4 6 5 6 7 10 9 4 6 8 11 9 4 5 6 10 9 5 6 6 10 9 4 6 7 11 10 5 6 7 10 8 53 87 29 5 3 14 11 5 17 27 5 3 5 3 2 3 6 4 5 5 10 8 4 5 6 9 8 3 4 6 9 8 3
2 1 1 2 3 3 3 4 9 7 3 4 5 10 8 3 3 4 10 7 3 3 4 11 8 2 3 4 10 7 3 4 4 9 6 100 186 14 2 1 14 12 4 13 14 3 3 2 1 1 1 3 3 3 4 9 6 2 2 4 8 6 2 3 4 9 7 2
3 1 1 3 4 4 5 6 9 6 4 4 7 9 7 4 6 8 9 7 5 5 6 10 8 4 6 7 9 8 5 5 6 10 8 101 176 17 3 2 13 12 5 15 18 3 3 3 1 1 3 4 4 5 5 9 7 5 5 6 10 8 5 5 7 9 8 4
6 2 2 4 6 3 4 6 10 8 4 5 6 10 8 3 5 7 11 9 3 4 6 10 9 4 5 6 10 8 3 5 5 10 8 56 103 25 2 1 16 14 5 16 25 5 3 4 2 2 3 6 4 4 5 9 7 3 4 6 10 7 3 5 6 9 7 3
3 1 1 2 5 3 3 4 9 8 2 3 5 9 7 3 3 4 11 8 2 3 4 10 8 3 4 5 10 7 2 3 3 10 7 74 157 18 2 1 14 13 5 15 12 2 2 3 0 0 1 4 2 2 3 9 6 2 3 4 9 7 3 3 4 8 6 2
5 2 2 3 6 3 4 6 10 8 4 4 5 11 8 3 3 4 10 8 3 4 4 10 7 4 3 5 9 8 3 4 5 8 7 85 120 15 2 1 16 13 6 17 24 2 3 5 2 2 3 6 4 5 5 8 6 3 3 4 10 7 3 5 5 10 8 3
4 1 0 2 1 2 3 3 9 7 3 3 3 9 7 2 3 4 10 8 3 3 4 10 7 2 2 3 9 6 2 3 4 9 7 80 254 15 2 2 14 14 6 18 8 1 3 1 0 0 1 2 2 2 3 7 4 2 2 3 8 4 1 2 3 7 4 2
4 2 1 2 4 3 4 5 9 6 4 5 6 9 7 3 4 5 10 7 4 5 6 10 7 4 5 5 9 7 5 6 6 9 6 78 186 19 2 1 14 13 5 12 15 3 3 3 2 1 2 3 2 3 4 8 6 3 4 4 9 7 3 4 5 8 7 3
3 0 1 2 2 2 2 4 9 7 3 3 4 10 7 2 4 5 10 9 3 3 4 9 7 3 3 3 10 6 2 3 4 8 5 64 163 13 2 1 15 11 4 11 9 2 2 1 0 1 1 2 2 2 3 7 4 2 3 4 9 7 2 3 3 10 6 2
6 0 0 3 4 3 3 4 10 7 3 3 4 9 6 3 3 4 9 6 3 3 3 9 7 4 6 6 10 7 4 4 6 9 7 70 130 15 2 1 17 14 4 15 17 4 3 5 0 0 2 4 3 4 5 9 7 4 4 5 9 7 3 4 5 9 7 3
6 3 2 2 6 4 4 5 9 7 3 3 4 9 8 3 4 5 10 7 3 4 4 9 8 4 5 6 11 6 3 5 5 9 7 62 130 22 3 2 16 14 5 16 22 4 3 4 2 1 3 5 4 5 5 9 7 3 4 5 9 6 3 4 4 10 7 5
2 1 1 2 2 2 3 3 9 5 2 3 3 8 5 2 2 3 10 5 2 2 3 9 4 2 2 3 8 5 1 3 3 9 6 136 350 11 2 1 14 15 6 16 5 0 1 1 1 0 1 1 1 2 2 6 3 2 2 2 8 4 1 2 2 7 5 2
5 1 1 3 5 3 3 4 9 8 3 4 5 10 8 3 4 4 9 7 3 5 6 9 7 3 4 5 10 8 3 4 6 10 8 75 134 21 3 1 15 13 5 16 19 3 3 4 1 1 2 5 3 4 5 8 7 3 4 5 8 6 3 4 5 9 7 3
4 1 1 3 3 2 3 4 10 8 3 4 5 10 7 3 4 5 10 7 3 3 4 9 6 3 4 5 11 8 3 3 4 11 10 85 205 13 2 1 15 13 7 14 11 1 2 2 1 1 2 2 2 2 3 8 4 2 2 3 7 4 2 3 4 9 7 2
5 2 1 3 4 4 5 6 11 8 4 4 5 10 9 4 5 5 10 9 3 4 5 9 8 3 3 3 9 8 4 4 5 10 8 99 206 21 4 2 17 13 5 15 13 2 1 4 1 0 2 3 3 3 4 9 8 3 4 5 10 9 3 3 4 10 9 2
3 1 1 2 2 2 3 3 9 6 2 2 3 9 8 1 2 3 9 7 2 3 3 8 5 3 3 4 9 7 2 3 2 8 5 98 >350 8 4 3 16 12 5 14 6 0 2 0 1 0 1 2 2 2 2 9 5 2 2 2 10 4 2 2 2 9 4 2
6 3 2 2 6 3 4 5 10 8 4 4 5 10 9 3 4 5 10 8 4 5 6 11 8 3 5 6 9 7 3 4 4 10 7 82 136 20 2 1 17 14 4 15 19 1 3 5 4 1 2 5 3 3 4 9 7 3 3 5 9 8 3 4 4 1 8 4
5 1 1 3 5 3 4 5 10 8 4 5 5 9 8 4 5 6 11 9 5 5 7 11 8 4 5 5 10 8 4 5 5 10 7 68 175 16 2 2 15 12 6 19 17 3 3 4 1 1 2 3 3 3 4 9 7 4 4 5 10 8 3 3 4 10 7 3
2 1 1 3 3 2 3 4 10 6 2 2 3 9 7 2 2 3 10 6 2 3 4 9 5 2 3 5 11 5 2 2 4 8 5 92 215 12 2 1 16 10 3 11 10 1 2 1 1 1 2 2 2 3 2 9 6 2 2 3 8 6 2 2 3 9 6 3
6 2 1 3 6 4 5 6 9 8 4 4 6 9 8 5 6 7 9 7 4 5 6 10 8 5 6 7 9 7 4 5 6 8 7 26 59 27 4 3 18 14 8 16 19 4 3 4 1 1 2 4 3 4 5 9 7 4 6 6 10 8 5 5 6 8 6 4
4 1 1 3 5 4 4 5 10 8 3 4 5 10 8 3 5 6 11 8 3 3 5 10 7 4 5 6 10 7 3 5 5 9 7 45 133 22 3 3 14 10 6 14 13 3 2 2 0 1 2 3 3 3 4 9 7 3 4 6 9 7 3 3 4 10 7 3
4 1 1 4 4 4 4 5 11 8 4 5 6 10 9 4 6 7 10 9 3 5 6 11 7 5 5 6 10 8 4 6 6 9 8 72 128 13 2 2 15 13 7 19 13 2 3 2 1 1 2 2 3 3 4 9 7 3 4 4 10 7 3 4 5 10 7 3
4 2 1 2 4 4 5 6 10 8 3 4 6 10 8 3 3 4 9 7 3 4 5 11 7 3 3 5 11 6 4 4 5 9 7 101 145 17 3 2 15 12 7 14 15 3 3 4 1 1 1 3 3 3 4 9 6 3 3 5 8 6 3 3 5 8 5 3
3 0 1 4 4 4 5 5 8 7 3 4 6 9 6 4 5 6 9 6 3 5 6 8 6 3 3 5 8 6 4 4 5 9 7 65 106 16 4 2 16 14 5 19 13 3 3 1 0 1 2 3 3 3 4 8 5 3 4 5 9 8 3 4 5 9 6 3
3 1 1 3 4 4 5 6 10 8 5 5 6 11 9 4 5 5 9 6 5 5 7 9 7 4 5 6 8 6 3 5 6 9 7 60 108 17 4 3 13 12 5 15 18 3 3 3 1 1 3 4 4 6 6 10 8 5 4 6 11 8 5 6 6 9 6 4
6 0 0 3 4 4 4 5 9 8 4 5 6 9 7 4 5 5 10 8 3 5 6 11 7 4 4 6 9 7 4 6 6 10 7 82 170 19 3 2 17 13 8 16 17 4 3 4 0 0 2 4 3 4 5 7 5 3 4 5 8 6 3 3 5 9 8 3
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6 7 11 8 4 5 6 10 9 5 5 7 10 9 48 94
5 6 8 8 5 5 6 10 9 5 5 6 11 9 55 200
3 5 8 6 2 2 4 9 7 2 4 4 9 6 55 200
4 5 10 6 3 4 4 9 6 3 4 6 10 6 78 130
3 5 9 6 2 3 3 8 5 3 4 4 9 6 107 180
3 5 9 7 3 3 4 11 6 2 3 4 11 9 76 189
3 5 8 7 3 3 5 9 6 2 2 4 9 7 61 105
5 6 9 8 4 5 7 11 8 5 6 6 10 9 57 120
5 6 9 7 4 4 5 10 9 3 5 6 10 8 65 135
5 6 10 8 4 5 6 10 8 3 5 6 11 9 80 210
4 6 10 6 3 4 6 10 8 3 5 5 9 6 80 136
4 6 10 8 3 5 6 11 9 3 5 5 10 8 41 73
3 4 8 6 2 2 3 6 4 2 2 3 7 5 101 214
3 4 10 6 2 2 3 9 7 2 3 3 8 6 74 154
4 5 10 9 4 5 6 10 8 4 5 6 11 9 47 89
2 3 9 6 3 3 4 10 7 2 3 4 10 7 117 191
5 6 10 9 4 5 5 9 7 4 5 6 10 7 95 163
4 5 10 7 3 4 5 9 8 4 4 6 10 7 57 106
3 3 10 6 2 3 3 8 6 2 3 3 8 6 67 157
3 4 9 7 3 3 4 10 6 3 4 5 11 7 80 117
2 2 7 3 2 2 3 9 4 1 3 3 8 4 98 263
4 6 9 7 3 5 6 9 7 3 4 5 10 7 86 199
2 4 9 6 3 3 4 8 4 3 3 3 11 6 79 166
4 4 9 7 3 4 5 9 7 4 5 7 9 7 68 125
6 5 10 8 5 6 6 9 7 4 5 5 11 7 73 148
2 2 7 3 1 2 3 8 4 2 2 3 9 4 158 350
4 5 10 8 4 4 6 11 7 3 4 6 11 7 76 141
3 4 10 9 3 4 4 9 9 3 3 4 9 7 111 214
4 4 10 9 3 4 5 9 8 3 4 4 10 9 105 350
2 3 8 3 2 2 3 8 4 2 2 2 9 5 136 >350
5 5 10 9 4 5 4 11 7 4 5 5 10 8 94 178
4 5 8 6 3 4 6 10 7 3 3 4 8 6 85 201
1 2 7 5 2 3 4 10 5 2 3 4 11 6 82 197
4 5 9 7 4 6 7 10 8 4 4 6 9 8 27 64
4 5 10 8 4 4 5 10 7 2 3 3 9 6 50 144
3 4 9 6 3 4 5 9 7 3 4 4 11 7 75 154
4 5 10 8 3 4 5 7 6 3 4 4 9 5 115 156
3 4 10 7 3 4 4 9 7 3 4 5 9 7 68 105
6 6 11 8 3 5 6 8 7 4 5 6 9 7 54 102
4 5 10 7 3 3 5 9 7 3 4 5 8 7 85 175
